<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) - Martínez, G - 2017 | Cochrane Library</title> <meta content="18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) - Martínez, G - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012883/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) - Martínez, G - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012883/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012883" name="dc.identifier" scheme="DOI"/> <meta content="18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)" name="citation_title"/> <meta content="Gabriel Martínez" name="citation_author"/> <meta content="gmartinez@cochrane.es" name="citation_author_email"/> <meta content="Robin WM Vernooij" name="citation_author"/> <meta content="Iberoamerican Cochrane Centre" name="citation_author_institution"/> <meta content="Paulina Fuentes Padilla" name="citation_author"/> <meta content="Javier Zamora" name="citation_author"/> <meta content="Ramon y Cajal Institute for Health Research (IRYCIS), CIBER Epidemiology and Public Health (CIBERESP), Madrid (Spain) and Women's Health Research Unit, Centre for Primary Care and Public Health, Queen Mary University of London" name="citation_author_institution"/> <meta content="Leon Flicker" name="citation_author"/> <meta content="University of Western Australia" name="citation_author_institution"/> <meta content="Xavier Bonfill Cosp" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD012883" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/11/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012883/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012883/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012883/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012883&amp;doi=10.1002/14651858.CD012883&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="fw9sVDQH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012883\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012883\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012883\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012883\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hr","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012883",title:"18F PET with florbetaben for the early diagnosis of Alzheimer\u0027s disease dementia and other dementias in people with mild cognitive impairment (MCI)",firstPublishedDate:"Nov 22, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=fw9sVDQH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012883&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012883';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012883/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012883/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012883%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012883/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012883/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012883/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012883/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012883" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012883/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012883" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012883/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012883/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2648 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012883" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/full#CD012883-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/full#CD012883-sec-0059"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/full#CD012883-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/full#CD012883-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/full#CD012883-sec-0029"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/full#CD012883-sec-0031"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/full#CD012883-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/full#CD012883-sec-0055"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012883/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/appendices#CD012883-sec-0064"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/table_n/CD012883StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/table_n/CD012883StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012883/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012883/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012883/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012883/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Diagnostic</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI) </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012883/information#CD012883-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Gabriel Martínez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012883/information#CD012883-cr-0003">Robin WM Vernooij</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012883/information#CD012883-cr-0004">Paulina Fuentes Padilla</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012883/information#CD012883-cr-0005">Javier Zamora</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012883/information#CD012883-cr-0006">Leon Flicker</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012883/information#CD012883-cr-0007">Xavier Bonfill Cosp</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012883/information/en#CD012883-sec-0072">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 November 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012883/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012883">https://doi.org/10.1002/14651858.CD012883</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012883-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012883-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012883-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012883-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012883-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012883-abs-0001" lang="en"> <section id="CD012883-sec-0001"> <h3 class="title" id="CD012883-sec-0001">Background</h3> <p><sup>18</sup>F‐florbetaben uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA‐AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using some amyloid biomarkers tests like <sup>18</sup>F‐florbetaben. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of <sup>18</sup>F‐florbetaben to predict the progression from MCI to Alzheimer’s disease dementia (ADD) or other dementias has not yet been systematically evaluated. </p> </section> <section id="CD012883-sec-0002"> <h3 class="title" id="CD012883-sec-0002">Objectives</h3> <p>To determine the DTA of the <sup>18</sup>F‐florbetaben PET scan for detecting people with MCI at time of performing the test who will clinically progress to ADD, other forms of dementia (non‐ADD), or any form of dementia at follow‐up. </p> </section> <section id="CD012883-sec-0003"> <h3 class="title" id="CD012883-sec-0003">Search methods</h3> <p>The most recent search for this review was performed in May 2017. We searched MEDLINE (OvidSP), Embase (OvidSP), PsycINFO (OvidSP), BIOSIS Citation Index (Thomson Reuters Web of Science), Web of Science Core Collection, including the Science Citation Index (Thomson Reuters Web of Science) and the Conference Proceedings Citation Index (Thomson Reuters Web of Science), LILACS (BIREME), CINAHL (EBSCOhost), ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">https://clinicaltrials.gov</a>), and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://www.who.int/ictrp/search/en/" target="_blank">http://www.who.int/ictrp/search/en/</a>). We also searched ALOIS, the Cochrane Dementia &amp; Cognitive Improvement Group’s specialised register of dementia studies (<a href="http://www.medicine.ox.ac.uk/alois/" target="_blank">http://www.medicine.ox.ac.uk/alois/</a>). We checked the reference lists of any relevant studies and systematic reviews, and performed citation tracking using the Science Citation Index to identify any additional relevant studies. No language or date restrictions were applied to electronic searches. </p> </section> <section id="CD012883-sec-0004"> <h3 class="title" id="CD012883-sec-0004">Selection criteria</h3> <p>We included studies that had prospectively defined cohorts with any accepted definition of MCI at time of performing the test and the use of <sup>18</sup>F‐florbetaben scan to evaluate the DTA of the progression from MCI to ADD or other forms of dementia. In addition, we only selected studies that applied a reference standard for Alzheimer’s dementia diagnosis, for example, the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS‐ADRDA) or Diagnostic and Statistical Manual of Mental Disorders‐IV (DSM‐IV) criteria. </p> </section> <section id="CD012883-sec-0005"> <h3 class="title" id="CD012883-sec-0005">Data collection and analysis</h3> <p>We screened all titles and abstracts identified in electronic‐database searches. Two review authors independently selected studies for inclusion and extracted data to create two‐by‐two tables, showing the binary test results cross‐classified with the binary reference standard. We used these data to calculate sensitivities, specificities, and their 95% confidence intervals. Two independent assessors performed quality assessment using the QUADAS‐2 tool plus some additional items to assess the methodological quality of the included studies. </p> </section> <section id="CD012883-sec-0006"> <h3 class="title" id="CD012883-sec-0006">Main results</h3> <p>Progression from MCI to ADD, any other form of dementia, and any form of dementia was evaluated in one study (Ong 2015). It reported data on 45 participants at four years of follow‐up; 21 participants met NINCDS‐ADRDA criteria for Alzheimer’s disease dementia at four years of follow‐up, the proportion converting to ADD was 47% of the 45 participants, and 11% of the 45 participants met criteria for other types of dementias (three cases of FrontoTemporal Dementia (FTD), one of Dementia with Lewy body (DLB), and one of Progressive Supranuclear Palsy (PSP)). We considered the study to be at high risk of bias in the domains of the reference standard, flow, and timing (QUADAS‐2). </p> <p>MCI to ADD; <sup>18</sup>F‐florbetaben PET scan analysed visually: the sensitivity was 100% (95% confidence interval (CI) 84% to 100%) and the specificity was 83% (95% CI 63% to 98%) (n = 45, 1 study). Analysed quantitatively: the sensitivity was 100% (95% CI 84% to 100%) and the specificity was 88% (95% CI 68% to 97%) for the diagnosis of ADD at follow‐up (n = 45, 1 study). </p> <p>MCI to any other form of dementia (non‐ADD);<sup>18</sup>F‐florbetaben PET scan analysed visually: the sensitivity was 0% (95% CI 0% to 52%) and the specificity was 38% (95% CI 23% to 54%) (n = 45, 1 study). Analysed quantitatively: the sensitivity was 0% (95% CI 0% to 52%) and the specificity was 40% (95% CI 25% to 57%) for the diagnosis of any other form of dementia at follow‐up (n = 45, 1 study). </p> <p>MCI to any form of dementia;<sup>18</sup>F‐florbetaben PET scan analysed visually: the sensitivity was 81% (95% CI 61% to 93%) and the specificity was 79% (95% CI 54% to 94%) (n = 45, 1 study). Analysed quantitatively: the sensitivity was 81% (95% CI 61% to 93%) and the specificity was 84% (95% CI 60% to 97%) for the diagnosis of any form of dementia at follow‐up (n = 45, 1 study). </p> </section> <section id="CD012883-sec-0007"> <h3 class="title" id="CD012883-sec-0007">Authors' conclusions</h3> <p>Although we were able to calculate one estimation of DTA in, especially, the prediction of progression from MCI to ADD at four years follow‐up, the small number of participants implies imprecision of sensitivity and specificity estimates. We cannot make any recommendation regarding the routine use of <sup>18</sup>F‐florbetaben in clinical practice based on one single study with 45 participants. <sup>18</sup>F‐florbetaben has high financial costs, therefore, clearly demonstrating its DTA and standardising the process of the <sup>18</sup>F‐florbetaben modality are important prior to its wider use. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012883-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012883-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012883-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012883-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012883-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012883-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012883-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012883-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012883-abs-0003" lang="en"> <h3>18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment </h3> <p><b>Review question:</b> In people with mild cognitive impairment (MCI), does using a <sup>18</sup>F PET scan with florbetaben predict progression to Alzheimer's disease dementia (ADD) and other dementias? </p> <p><b>Background</b> <br/> Due to global ageing, the number of people with dementia is expected to increase dramatically in the next few decades. Diagnosing dementia at an early stage is desirable, but there is no widespread agreement on the best approach. A range of simple pen and paper tests used by healthcare professionals can assess people with poor memory or cognitive impairment. Whether or not using special PET scans that detect amyloid —one of the hallmarks of Alzheimer's disease— improves our ability to predict the progression from MCI to ADD or other forms of dementia remains unclear. Since these tests are expensive, it is important that they provide additional benefits. </p> <p><b>Aim</b> </p> <p>We aimed to evaluate the accuracy of the <sup>18</sup>F‐florbetaben PET scan in identifying those people with MCI who clinically progress to ADD, other types of dementia, or any form of dementia over a period of time. </p> <p><b>Study characteristics</b> <br/> The evidence is current to May 2017. We found 1 study including 45 participants with MCI with a follow‐up of 4 years; gender was not reported and the median age for those with a PET‐positive scan by quantitative assessment was 73.5 years old. For those with a PET‐negative scan the mean age was 71.8 years old. Participants were mainly recruited from local memory clinics. </p> <p>Study funding sources: the study was funded by the test manufacturer.</p> <p><b>Quality of the evidence</b><br/> The main limitation of this review was that our findings were based on only one study, with not enough details on how the participants were selected. The study was considered to be at high risk of bias, since the final ADD diagnosis was not established separately from the scan results, and due to potential conflicts of interest detected. </p> <p><b>Key findings</b> <br/> In this review, based on only one study, we found that the <sup>18</sup>F‐florbetaben PET scan, as a single test with visual assessment, correctly classified 100% of the participants who will progress to ADD and 83% of the participants who did not progress to ADD at four years follow‐up. This means that in a cohort with 100 participants with MCI, 47 of whom will progress to ADD, we would expect that all those 47 MCI participants would test positive with the <sup>18</sup>F‐florbetaben scan and that 0 participants would be falsely negative (i.e. none of the 47 participants would have a negative test and yet progress to ADD). In addition, we would expect 44 of 53 participants who did not progress to ADD to be <sup>18</sup>F‐florbetaben‐negative and 9 to be falsely positive (i.e. 9 of the 53 participants would have a positive test but not progress to ADD). </p> <p>The small size of the included study lowered our confidence on these estimates of accuracy and it is still possible that the test is considerably less accurate than these results suggest. </p> <p>We conclude that <sup>18</sup>F‐florbetaben imaging is a promising test to predict the progression from MCI to ADD; however, we need more studies to clearly demonstrate its accuracy. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012883-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012883-sec-0059"></div> <h3 class="title" id="CD012883-sec-0060">Implications for practice</h3> <section id="CD012883-sec-0060"> <p>Today, the use of <sup>18</sup>F‐florbetaben is not indicated in people with MCI (FDA and EMA) except in clinical trials and research studies. However, the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association have proposed the usage of amyloid PET in people with persistent or progressive unexplained MCI (<a href="./references#CD012883-bbs2-0048" title="JohnsonKA , MinoshimaS , BohnenNI , DonohoeKJ , FosterNL , HerscovitchP , et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Journal of Nuclear Medicine2013;54(3):476‐90. ">Johnson 2013</a>). The DTA of <sup>18</sup>F‐florbetaben PET scans, as determined in this SR, suggests a limited use due to a lack of information based only on one study with 45 participants to predict the progression from MCI to ADD and any form of dementia. Despite this, in the sole study, the sensitivity was 100% and the specificity was 83% for visual assessment analysis to predict the progression to ADD and the sensitivity was 81% and the sensitivity was 79% to predict the progression to any form of dementia. The prediction to other forms of dementia (non‐ADD) was poor, however, this could be explained because the pathology of the other neurodegenerative conditions is not based on the Aβ plaques. Finally, we have to consider the risk of bias due to the access to medical tests and medical records by the neurologist who made the diagnosis at four years follow‐up, because this could overestimate the DTA of <sup>18</sup>F‐florbetaben (<a href="./references#CD012883-bbs2-0052" title="LijmerJG , MolBW , HeisterkampS , BonselGJ , PrinsMH , Van derMeulenJH , et al. Empirical evidence of design‐related bias in studies of diagnostic tests. JAMA1999;282(11):1061‐6. ">Lijmer 1999</a>). Due to the aforementioned and the methodological limitations of the included study, it is not possible to recommend the routine use of <sup>18</sup>F‐florbetaben in clinical practice. The <sup>18</sup>F‐florbetaben biomarker is expensive, therefore, it is important to clearly demonstrate its DTA and to standardise the process for the diagnostic modality prior to it being widely used. </p> </section> <h3 class="title" id="CD012883-sec-0061">Implications for research</h3> <section id="CD012883-sec-0061"> <p>The FDA and EMA had established the <sup>18</sup>F‐florbetaben positivity criteria in order that the use in ADD patients' evaluation and use in people with MCI is accepted in research settings and clinical trials (<a href="./references#CD012883-bbs2-0008" title="AlbertMS , DeKoskyST , DicksonD , DuboisB , FeldmanHH , FoxNC , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(3):270‐9. ">Albert 2011</a>). On the other hand, it has been proposed for use in clinical practice by the Nuclear Medicine Society and the Alzheimer's Association (<a href="./references#CD012883-bbs2-0048" title="JohnsonKA , MinoshimaS , BohnenNI , DonohoeKJ , FosterNL , HerscovitchP , et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Journal of Nuclear Medicine2013;54(3):476‐90. ">Johnson 2013</a>). </p> <p>The interpretation of the results of the <sup>18</sup>F‐florbetaben PET scan studies could be difficult due to the use of different methods to define the result of the test. It is still used in many studies with different SUVR, visual assessment or both, and this promotes different accuracies for the tracer, even in people with ADD when they are compared with healthy people without ADD. Therefore, it is necessary to consider that visual assessment is the most important option to interpret the <sup>18</sup>F‐florbetaben PET scan, because this is the approach to the interpretation established by FDA and EMA (<a href="./references#CD012883-bbs2-0033" title="Food , DrugAdministration . Neuroceq. www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf (accessed 08/04/2015). ">FDA 2014</a>, <a href="./references#CD012883-bbs2-0030" title="European Medicines Agency. Neuraceq. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002553/WC500162592.pdf (accessed 8th April 2015). ">EMA 2014</a>). </p> <p>Moreover, clinical assessment in people with memory complaints is not always undertaken with only one test, as clinical assessment could use different tests, like volumetric hippocampal MRI, FDG‐PET, SPECT, CSF, and others. This makes sense because neurodegenerative diseases are complex disorders with occasionally multiple and overlapping pathophysiological processes, and multitracer imaging may be helpful in combining metabolic, inflammation, or apoptosis markers with those labelling typical protein aggregations seen in the progression of MCI to Alzheimer’s disease dementia. In future, various PET imaging modalities are needed to evaluate the usefulness of the various PET tracers as predictors of progression to Alzheimer’s disease dementia in MCI studies with clinical follow‐up. There is a hypothesis that amyloid deposition is an early event in Alzheimer’s disease that reaches a relative plateau even at the MCI stage, while downstream biomarkers measure neuronal loss and dysfunction, and cognitive measures are more dynamic at the symptomatic disease stage (<a href="./references#CD012883-bbs2-0046" title="JackCRJr , KnopmanDS , JagustWJ , ShawLM , AisenPS , WeinerMW . Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet. Neurology2010;9(1):119‐28. ">Jack 2010</a>). Based on this hypothesis, the combination of structural imaging, functional imaging, and cognitive tests may be better predictors of when an individual will convert. However, in this way, the Ong 2015 study showed that a <sup>18</sup>F‐florbetaben PET positive result predicted progression after adjusting for both aMCI status and hippocampal atrophy evaluated with sMRI (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). Nevertheless, there is a lack of studies with <sup>18</sup>F‐florbetaben combined with other tests. </p> <p>Additionally, if we consider the hierarchical evidence needed for the level of efficacy of diagnostic imaging tests, we are currently in the second step of six according to Herscovitch (<a href="./references#CD012883-bbs2-0042" title="HerscovitchP . Regulatory approval and insurance reimbursement: the final steps in clinical translation of amyloid brain imaging. Clinical and Translational Imaging2015;3:75‐7. ">Herscovitch 2015</a>): technical efficacy, diagnostic accuracy efficacy, diagnostic thinking efficacy, therapeutic impact, patient health outcomes, and, finally, societal efficacy. Therefore, we need further research about accuracy before progressing to the other steps with their specific studies before we can incorporate the <sup>18</sup>F‐florbetaben PET scan into clinical practice. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012883-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012883-sec-0022"></div> <div class="table" id="CD012883-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">Diagnostic test accuracy of 18F‐florbetaben to predict the progression to ADD, any other form of dementia (non‐ADD) or any form of dementia in people with MCI</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>What is the diagnostic accuracy of <sup>18</sup>F‐florbetaben PET amyloid biomarker for predict progression to ADD or any other form of dementia (non‐ADD) or any form of dementia in people with MCI? </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Descriptive</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Patient population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Participants diagnosed with MCI at baseline using any of the Petersen criteria or Winblad criteria or CDR = 0.5 or any 16 definitions included by Matthews (<a href="./references#CD012883-bbs2-0056" title="MatthewsFE , StephanBC , McKeithIG , BondJ , BrayneC , Medical Research Council Cognitive Function and Ageing Study. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society2008;56(8):1424‐33. ">Matthews 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sources of referral</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Memory clinic</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MCI criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Petersen criteria 2004 and Winblad 2004 (<a href="./references#CD012883-bbs2-0072" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004;256(3):183‐94. ">Petersen 2004</a>; <a href="./references#CD012883-bbs2-0097" title="WinbladB , PalmerK , KivipeltoM , JelicV , FratiglioniL , WahlundLO , et al. Mild cognitive impairment ‐ beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine2004;256(3):240‐6. ">Winblad 2004</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sampling procedure</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>unclear</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prior testing</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The only testing prior performing the <sup>18</sup>F‐florbetaben PET amyloid biomarker was the application of diagnostic criteria for identifying participants with MCI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Settings</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Secondary care</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben PET </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Threshold prespecified at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Threshold interpretation</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Visual and quantitative</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Threshold</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Visual: if any tracer uptake was visible in any of the frontal, parietal, temporal, and posterior cingulate/precuneus cortices </p> <p>SUVR (Standardised Uptake Volume ratio) of ROI: &gt; 1.45</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben retention region </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Visual: frontal, parietal, temporal, and posterior cingulate/precuneus cortices</p> <p>Global cortex (SUVR)</p> <p>SUVR: Global cortex</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference Standard</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>For Alzheimer’s disease dementia:</p> <p>NINCDS‐ADRDA (<a href="./references#CD012883-bbs2-0061" title="McKhannGM , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;34(7):939‐44. ">McKhann 1984</a>) </p> <p>For Lewy body dementia:</p> <p>McKeith criteria (<a href="./references#CD012883-bbs2-0060" title="McKeithIG , DicksonDW , LoweJ , EmreM , O'BrienJT , FeldmanH , et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology2005;65(12):1863‐72. ">McKeith 2005</a>) </p> <p>For frontotemporal dementia:</p> <p>Lund criteria (<a href="./references#CD012883-bbs2-0017" title="BrunA , EnglundB , GustafsonL , PassantU , MannDMA , NearyD , et al. Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry1994;57(4):416‐8. ">Brun 1994</a>) </p> <p>For progressive supranuclear palsy:</p> <p>Preliminary NINDS criteria (<a href="./references#CD012883-bbs2-0040" title="HauwJJ , DanielSE , DicksonD , HoroupianDS , JellingerK , LantosPL , et al. Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy). Neurology1994;44(11):2015‐9. ">Hauw 1994</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Progression from MCI to Alzheimer’s disease dementia or any other forms of dementia or any form of dementia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Included studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Prospectively well‐defined cohorts with any accepted definition of MCI (as above). One study (N = 45 participants) was included. Number of participants included in analysis: 45. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Patient characteristics were poorly reported. Reference standard diagnosis was made with knowledge of the index test. Applicability concerns were high in reference standard. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limitations</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>We were not able to calculate a summary of sensitivity and specificity due to insufficient number of studies. </p> <p>Investigation of heterogeneity and sensitivity analysis were not done due to insufficient number of studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Cases/Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Sensitivity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Specificity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Consequences in a cohort of 100</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion converting<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missed cases<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overdiagnosed</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alzheimer's disease dementia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben (visual assessment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (95% CI 84% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% (95% CI 63% to 95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben (SUVR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (95% CI 84% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88% (95% CI 68% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any other form of dementia (non‐ADD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben (visual assessment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% (95% CI 0% to 52%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38% (95% CI 23% to 54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben (SUVR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% (95% CI 0% to 52%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40% (95% CI 25% to 57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any form of dementia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben (visual assessment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81% (95% CI 61% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (95% CI 54% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben (SUVR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81% (95% CI 61% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (95% CI 60% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Investigation of heterogeneity and sensitivity analysis</b>: The planned investigations of heterogeneity or sensitivity analyses were not possible due to a limited number of studies available for each analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Conclusions:</b><sup>18</sup>F‐florbetaben PET scan has a good sensitivity achieved especially in predicting the progression from MCI to ADD. The quality of evidence was weak because it was based on only one study (45 participants) and there was high risk of bias due to the knowledge of the reference standard to do the diagnosis at four‐year follow‐up and due to possible conflict of interest detected. There is a need for conducting studies using standardised <sup>18</sup>F‐florbetaben PET scan methodology in larger populations. Regarding the aforementioned we do not recommend the use in clinical practice until the DTA performance will be clearly demonstrated. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1. Proportion converting to ADD or any other form of dementia (non‐ADD) or any form of dementia in the included study</sup> </p> <p><sup>2. Missed and overdiagnosed numbers were computed using the proportion converting to the target condition.</sup> </p> <p><sup>ADD: Alzheimer's disease dementia<br/> CDR: Clinical Dementia Rating<br/> MCI: Mild cognitive impairment<br/> NINCDS‐ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association</sup> </p> <p><sup>NINDS: National Institute of Neurological Disorders and Stroke<br/> PET: Positron emission tomography<br/> ROI: Region of interest<br/> SUVR: Standardised uptake value ratio</sup> </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012883-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012883-sec-0023"></div> <p>Dementia is a syndrome due to a brain disease — usually of a chronic or progressive nature — in which there is disturbance of multiple higher cortical functions, including memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement. However, consciousness remains unaffected. See the glossary in <a href="./appendices#CD012883-sec-0065">Appendix 1</a>. The impairments of cognitive function are commonly accompanied, and occasionally preceded, by a deterioration in emotional control, social behaviour, and motivation, and the impairment is sufficient to interfere with everyday activities. Dementia is a collection of different subtypes distinguished by the underlying pathology. ADD is the most common form of dementia and other important pathologies associated with dementia are vascular disease, Lewy bodies, and frontotemporal pathology (<a href="./references#CD012883-bbs2-0096" title="World Health Organization, Alzheimer's Disease International. Dementia: a public health priority. www.who.int/mental_health/publications/dementia_report_2012/en/ (accessed 23th September 2015). ">WHO 2012</a>). </p> <p>Dementia is a serious worldwide public health problem, with a prevalence of 4.7% in adults older than 60 years (6.2% and 6.5% in Europe and the Americas, respectively). Due to its prevalence in older people, it is expected that the number of people with dementia will increase dramatically. Consequently, in the year 2050, an expected number of 115 million people will have dementia. This will result in a considerable economic burden, which currently stands at 1% of the world's Gross National Product (GNP) in direct and indirect costs (<a href="./references#CD012883-bbs2-0096" title="World Health Organization, Alzheimer's Disease International. Dementia: a public health priority. www.who.int/mental_health/publications/dementia_report_2012/en/ (accessed 23th September 2015). ">WHO 2012</a>). These financial costs are in addition to the devastating personal and social consequences of the condition. </p> <p>The definition of MCI applies to people without evidence of significant deterioration in activities of daily living, but with subjective memory complaints and cognitive impairment detected by standardised tests. MCI often precedes clinical dementia, but there is no consensus regarding how to operationalise the MCI diagnosis. There are several clinical criteria to define which people have MCI, including the Petersen criteria or Petersen Revised Criteria (<a href="./references#CD012883-bbs2-0071" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999;56(3):303‐8. ">Petersen 1999</a>; <a href="./references#CD012883-bbs2-0072" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004;256(3):183‐94. ">Petersen 2004</a>; <a href="./references#CD012883-bbs2-0097" title="WinbladB , PalmerK , KivipeltoM , JelicV , FratiglioniL , WahlundLO , et al. Mild cognitive impairment ‐ beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine2004;256(3):240‐6. ">Winblad 2004</a>), Clinical Dementia Rating (CDR = 0.5) (<a href="./references#CD012883-bbs2-0064" title="MorrisJC . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology1993;43(11):2412‐4. ">Morris 1993</a>), or 16 other different classifications of MCI (<a href="./references#CD012883-bbs2-0056" title="MatthewsFE , StephanBC , McKeithIG , BondJ , BrayneC , Medical Research Council Cognitive Function and Ageing Study. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society2008;56(8):1424‐33. ">Matthews 2008</a>). </p> <p>A diagnosis of MCI reputedly allows testing of preventive interventions that would slow the progression of MCI to dementia. If the progression of MCI to dementia could be deferred by five years, the prevalence of dementia would decrease by 43% in 2050 (<a href="./references#CD012883-bbs2-0009" title="Alzheimer's Association. Changing the trajectory of Alzheimer's disease: a national imperative. http://www.alzheimersreadingroom.com/2010/05/changing‐trajectory‐of‐alzheimers.html (accessed prior to 12 October 2017). ">Alzheimer's Association 2010</a>). MCI has an annual progression rate to ADD from 5% to 15%. However, not every person with MCI develops dementia, and a significant number of people recover or stabilise. Therefore, future research should try to clarify which people with MCI develop dementia in order to be able to focus specifically on people who are at high risk of developing dementia. This may possibly explain the failure of therapy to alter the progression to dementia in people with MCI. Other aspects that may contribute to this failure are the disparity in diagnostic criteria and different settings of the studied participants: community, primary, secondary, and research centres (<a href="./references#CD012883-bbs2-0018" title="BruscoliM , LovestoneS . Is MCI really just early dementia? A systematic review of conversion studies. International Psychogeriatrics2004;16(2):129‐40. ">Bruscoli 2004</a>; <a href="./references#CD012883-bbs2-0057" title="MattssonN , ZetterbergH , HanssonO , AndreasenN , ParnettiL , JonssonM , et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA2009;302(4):385‐93. ">Mattsson 2009</a>; <a href="./references#CD012883-bbs2-0071" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999;56(3):303‐8. ">Petersen 1999</a>; <a href="./references#CD012883-bbs2-0073" title="PetersenRC , RobertsRO , KnopmanDS , BoeveBF , GedaYE , IvnikRJ , et al. Mild cognitive impairment: ten years later. Archives of Neurology2009;66(12):1447‐55. ">Petersen 2009</a>). </p> <p>The definition of Alzheimer's disease pathology is over 100 years old. This pathology includes neuritic plaques that contain deposits of amyloid beta (Aβ) and neurofibrillary tangles (<a href="./references#CD012883-bbs2-0037" title="GoedertM , SpillantiniMG . A century of Alzheimer's disease. Science2006;314(5800):777‐81. ">Goedert 2006</a>). This pathology is present in approximately 84% of all people with dementia (<a href="./references#CD012883-bbs2-0085" title="SchneiderJA , ArvanitakisZ , BangW , BennettDA . Mixed brain pathologies account for most dementia cases in community‐dwelling older persons. Neurology2007;69(24):2197‐204. ">Schneider 2007</a>). Furthermore, Alzheimer's disease pathology is found in 88% of people diagnosed with probable ADD (<a href="./references#CD012883-bbs2-0086" title="SchneiderJA , ArvanitakisZ , LeurgansSE , BennettDA . The neuropathology of probable Alzheimer disease and mild cognitive impairment. Annals of Neurology2009;66(2):200‐8. ">Schneider 2009</a>). Despite this, Alzheimer's disease pathology may be found concomitantly at autopsy in people thought to have other forms of dementia, such as vascular dementia, Lewy body dementia, or frontotemporal dementia (FTD) (<a href="./references#CD012883-bbs2-0047" title="JellingerK . Clinicopathological analysis of dementia disorders in the elderly ‐ an update. Journal of Alzheimer's Disease2006;9(Supplement 3):61‐70. ">Jellinger 2006</a>). Furthermore, at least five common pathologies have been found in the brains of people who died and were thought to have ADD prior to death (<a href="./references#CD012883-bbs2-0094" title="WhiteL . Brain lesions at autopsy in older Japanese‐American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu‐Asia aging study. Journal of Alzheimer's Disease2009;18(3):713‐25. ">White 2009</a>). Also, Alzheimer's disease pathology was found in 42% of community‐dwelling older people without dementia (<a href="./references#CD012883-bbs2-0085" title="SchneiderJA , ArvanitakisZ , BangW , BennettDA . Mixed brain pathologies account for most dementia cases in community‐dwelling older persons. Neurology2007;69(24):2197‐204. ">Schneider 2007</a>). This has generated controversy about the importance of the presence of Alzheimer's disease pathology. The pathology can be associated with aging per se, and, for older people, the relationship between amyloid plaque burden and cognitive impairment diminishes as age progresses (<a href="./references#CD012883-bbs2-0084" title="SavvaGM , WhartonSB , IncePG , ForsterG , MatthewsFE , BrayneC , Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia. New England Journal of Medicine2009;360(22):2302‐9. ">Savva 2009</a>). Thus, this pathology could be an epiphenomenon associated with the presence of dementia, e.g. a by‐product of repair mechanisms by vascular damage (<a href="./references#CD012883-bbs2-0025" title="De laTorreJC . Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet. Neurology2004;3(3):184‐90. ">De la Torre 2004</a>; <a href="./references#CD012883-bbs2-0035" title="Garcia‐AllozaM , GregoryJ , KuchibhotlaKV , FineS , WeiY , AyataC , et al. Cerebrovascular lesions induce transient β‐amyloid deposition. Brain2011;134(12):3697‐707. ">Garcia‐Alloza 2011</a>). On the other hand, this controversy could be because our clinical diagnostic criteria have not had enough accuracy to diagnose Alzheimer's disease that is detected by histopathology in postmortem studies (<a href="./references#CD012883-bbs2-0044" title="HymanBT , PhelpsCH , BeachTG , BigioEH , CairnsNJ , CarrilloMC , et al. National Institute on Aging‐Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(1):1‐13. ">Hyman 2012</a>). In addition, other researchers think that there is not a real controversy about the amyloid hypothesis, because the amyloid cascade and the Aβ deposition have a primary role in Alzheimer's disease (<a href="./references#CD012883-bbs2-0088" title="SelkoeDJ , HardyJ . The amyloid hypothesis of Alzheimer's disease at 25 years. European Molecular Biology Organization2016;8(6):595‐608. ">Selkoe 2016</a>). </p> <p>More recently, the development of Aβ pathology biomarkers in vivo has been suggested as an important advance as a diagnostic tool in the field of Alzheimer's disease, and has promoted the creation of new diagnostic criteria for people without symptoms (preclinical stages), people with MCI, and people with ADD, based on the presence of biomarkers of Alzheimer's disease. These have included Aβ tracers by positron emission tomography (PET) (<a href="./references#CD012883-bbs2-0008" title="AlbertMS , DeKoskyST , DicksonD , DuboisB , FeldmanHH , FoxNC , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(3):270‐9. ">Albert 2011</a>; <a href="./references#CD012883-bbs2-0026" title="DuboisB , FeldmanHH , JacovaC , HampelH , MolinuevoJL , BlennowK , et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG‐2 criteria. Lancet. Neurology2014;13(6):614‐29. ">Dubois 2014</a>; <a href="./references#CD012883-bbs2-0062" title="McKhannGM , KnopmanDS , ChertkowH , HymanBT , JackCRJr , KawasCH , et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(3):263‐9. ">McKhann 2011</a>; <a href="./references#CD012883-bbs2-0091" title="SperlingRA , AisenPS , BeckettLA , BennettDA , CraftS , FaganAM , et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(3):280‐92. ">Sperling 2011</a>). However, uncertainties regarding the usability of biomarkers in the diagnosis of dementia still exist, mainly due to variation between biomarker types, criteria for positivity, and differences in methodology (<a href="./references#CD012883-bbs2-0068" title="Noel‐StorrAH , FlickerL , RitchieCW , NguyenGH , GuptaT , WoodP , et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimer's &amp; Dementia2013;9(3):e96‐105. ">Noel‐Storr 2013</a>). This prompted an important initiative, the Standards for Reporting of Diagnostic Accuracy Studies in dementia studies (STARDdem) statement (<a href="./references#CD012883-bbs2-0069" title="Noel‐StorrAH , McCleeryJM , RichardE , RitchieCW , FlickerL , CullumSJ , et al. Reporting standards for studies of diagnostic test accuracy in dementia: the STARDdem Initiative. Neurology2014;83(4):364‐73. ">Noel‐Storr 2014</a>). Consequently, clinical properties of dementia biomarkers should not be assumed, and formal systematic evaluations of sensitivity, specificity, and other properties of biomarkers should be performed (<a href="./references#CD012883-bbs2-0023" title="DavisDHJ , CreavinST , Noel‐StorrA , QuinnTJ , SmailagicN , HydeC , et al. Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross‐sectional and delayed‐verification studies. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010460] ">Davis 2013</a>). </p> <p>PET is an imaging technique using compounds labelled with short‐lived positron‐emitting radionuclides. The use of Aβ ligands permits the in vivo detection of amyloid deposition in the brain. <sup>18</sup>F‐florbetaben is a stilbene derivative, which was first described 12 years ago, and is characterised by a high affinity for Aβ. <sup>18</sup>F‐florbetaben has excellent uptake by brain tissue and washout kinetics in mice (<a href="./references#CD012883-bbs2-0098" title="ZhangW , OyaS , KungMP , HouC , MaierDL , KungHF . F‐18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nuclear Medicine and Biology2005;32(8):799‐809. ">Zhang 2005</a>). <sup>18</sup>F‐florbetaben was evaluated in people with ADD, healthy people without ADD (<a href="./references#CD012883-bbs2-0014" title="BarthelH , GertzHJ , DreselS , PetersO , BartensteinP , BuergerK , et al. Cerebral amyloid‐β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet. Neurology2011;10(5):424‐35. ">Barthel 2011</a>), and people with other dementias (<a href="./references#CD012883-bbs2-0092" title="VillemagneVL , OngK , MulliganRS , HollG , PejoskaS , JonesG , et al. Amyloid imaging with (18)F‐florbetaben in Alzheimer disease and other dementias. Journal of Nuclear Medicine2011;52(8):1210‐7. ">Villemagne 2011</a>). </p> <p>The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved <sup>18</sup>F‐florbetaben for Aβ binding. These agencies have stated that a negative scan indicates sparse or no plaques, which is inconsistent with a diagnosis of ADD, thus effectively excluding this diagnosis. A positive <sup>18</sup>F‐florbetaben scan indicates moderate to frequent presence of neuritic amyloid plaques. However, this might also occur in people with other neurological conditions and in older adults with normal cognition. Therefore, it should be combined with other diagnostic evaluations or instruments and cannot be used solely to assess the risk of progression to ADD. Therefore, a positive result of an <sup>18</sup>F‐florbetaben scan does not establish the diagnosis of ADD or any other cognitive disorder definitely, and it should be combined with other diagnostic evaluations or instruments. Additionally, the effectiveness and safety of the tests have not been established by predicting development of dementia or other neurological conditions, or by monitoring responses to therapies (<a href="./references#CD012883-bbs2-0030" title="European Medicines Agency. Neuraceq. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002553/WC500162592.pdf (accessed 8th April 2015). ">EMA 2014</a>; <a href="./references#CD012883-bbs2-0033" title="Food , DrugAdministration . Neuroceq. www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf (accessed 08/04/2015). ">FDA 2014</a>). </p> <p>Despite not being approved for this purpose by the regulatory agencies, research has been conducted in people with MCI to determine whether biomarkers, such as <sup>18</sup>F‐florbetaben for Aβ, increase the risk of developing dementia over time. The evidence for this is uncertain. For this and other reasons, the NIA‐AA in the USA established two different criteria for MCI. Firstly, they established the Core Clinical Criteria for use in all clinical settings, without use of biomarkers, and characterised by concerns regarding a change in cognition with impairment in one or more cognitive domains with preservation of independence in functional abilities, therefore no dementia. Secondly, they established the Clinical Research Criteria, which incorporate the use of biomarkers, such as PET amyloid scans, intended for use exclusively in research settings, including academic centres and clinical trials. This will help determine whether positive scans increase the likelihood of progression from MCI to clinical dementia (<a href="./references#CD012883-bbs2-0008" title="AlbertMS , DeKoskyST , DicksonD , DuboisB , FeldmanHH , FoxNC , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(3):270‐9. ">Albert 2011</a>). Lastly, it is hoped that people with MCI and positive scans will 'enrich' clinical trials, and more people who will progress to dementia in a shorter time will be included to allow more efficient studies of treatments and prevention strategies of ADD (<a href="./references#CD012883-bbs2-0020" title="The Centers for Medicare &amp; Medicaid Services. Decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG‐00431N). cms.gov/medicare‐coverage‐database/details/nca‐decision‐memo.aspx?NCAId=265 (accessed 08 October 2015). ">CMS 2013</a>). </p> <p>An assumption for some researchers, and one on which this systematic review (SR) is predicated, is that if a person has both MCI and the pathology of Alzheimer's disease and develops clinical ADD subsequently, then the cause of the initial MCI and of the ADD was the Alzheimer’s pathology. Our approach is an example of assessing diagnostic test accuracy (DTA) using delayed verification of diagnosis. Instead of the reference standard being based on pathology, it is based on a clinical standard and the progression from MCI to ADD, or any other form of non‐ADD, or any dementia. Although, for the reasons stated above, a degree of unreliability has been introduced, defining progression has the advantage of being based on what matters most to people with MCI, their families, and clinicians involved in their care. </p> <p><sup>18</sup>F‐florbetaben PET scan is considered the diagnostic marker of interest, and in this SR we assessed the DTA of <sup>18</sup>F‐florbetaben Aβ binding in the brain and progression of the following: </p> <p> <ul id="CD012883-list-0001"> <li> <p>From MCI to ADD.</p> </li> <li> <p>From MCI to any other form of non‐ADD.</p> </li> <li> <p>From MCI to any form of dementia</p> </li> </ul> </p> <p>This SR belongs to a series of SRs regarding PET biomarkers for Aβ, including <sup>18</sup>F‐florbetapir and <sup>18</sup>F‐flutemetamol (<a href="./references#CD012883-bbs2-0055" title="MartínezG , FlickerL , VernooijRWM , Fuentes PadillaP , ZamoraJ , FigulsMRI , et al. 18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD012216] ">Martínez 2016</a>). </p> <section id="CD012883-sec-0024"> <h3 class="title" id="CD012883-sec-0024">Target condition being diagnosed</h3> <p>This SR assessed the following three target conditions.</p> <p> <ul id="CD012883-list-0002"> <li> <p>ADD (progression from MCI to ADD).</p> </li> <li> <p>Any other form of dementia (progression from MCI to any other form of non‐ADD).</p> </li> <li> <p>Any form of dementia (progression from MCI to any form of dementia).</p> </li> </ul> </p> <p>We compared the index test results obtained at baseline with the results of the reference standards obtained at follow‐up (delayed verification). </p> </section> <section id="CD012883-sec-0025"> <h3 class="title" id="CD012883-sec-0025">Index test(s)</h3> <p>The <sup>18</sup>F‐florbetaben scan is an index test for the detection of Aβ deposition in the brain region of interest (ROI). The ROI is a selected brain area that physicians create for further study in various anatomical areas of the brain. <sup>18</sup>F‐florbetaben is a molecular biomarker, described as </p> <p>[<sup>18</sup>F]BAY 94‐9172, trans‐4‐(N‐methyl‐amino)‐4’‐2‐[2‐(2‐[<sup>18</sup>F]fluoro‐ethoxy)‐ethoxy]‐ethoxy‐stilbene and also referred to as BAY 94‐9172 or ZK 6013443, which is a polyethylene glycol stilbene derivative (<a href="./references#CD012883-bbs2-0098" title="ZhangW , OyaS , KungMP , HouC , MaierDL , KungHF . F‐18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nuclear Medicine and Biology2005;32(8):799‐809. ">Zhang 2005</a>). </p> <p><b>Image Interpretation</b> </p> <p>Both the FDA and EMA have described the criteria for <sup>18</sup>F‐florbetaben Aβ positivity (<a href="./references#CD012883-bbs2-0030" title="European Medicines Agency. Neuraceq. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002553/WC500162592.pdf (accessed 8th April 2015). ">EMA 2014</a>; <a href="./references#CD012883-bbs2-0033" title="Food , DrugAdministration . Neuroceq. www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf (accessed 08/04/2015). ">FDA 2014</a>). </p> <p><sup>18</sup>F‐florbetaben diagnosis is by PET image assessment, and is defined as positive if the analysis shows the following. </p> <p> <ul id="CD012883-list-0003"> <li> <p>Moderate or smaller area(s) of tracer uptake equal to or higher than that presented in the white matter: extending beyond the white matter rim to the outer cortical margin involving the majority of the slices within the respective region. </p> </li> <li> <p>Pronounced Aβ deposition (a large confluent area of tracer uptake equal to or higher than that presented in white matter extending beyond the white matter rim to the outer cortical margin and involving the entire region including the majority of slices within the respective region) in the grey matter of the following four brain regions: the temporal lobes, the frontal lobes, the posterior cingulate cortex/precuneus, and the parietal lobes. </p> </li> </ul> </p> <p>Readers trained in PET images with the <sup>18</sup>F‐florbetaben should interpret the Aβ PET images made with this ligand (<a href="./references#CD012883-bbs2-0030" title="European Medicines Agency. Neuraceq. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002553/WC500162592.pdf (accessed 8th April 2015). ">EMA 2014</a>; <a href="./references#CD012883-bbs2-0033" title="Food , DrugAdministration . Neuroceq. www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf (accessed 08/04/2015). ">FDA 2014</a>). </p> <p>Before the FDA and EMA described the criteria for <sup>18</sup>F‐florbetaben scan positivity, the diagnosis of dementia was made using different thresholds. Therefore, we planned to use the FDA or EMA criteria applied in each included study to classify participants as either test‐positive or test‐negative, or, alternatively, if <sup>18</sup>F‐florbetaben Aβ uptake and retention exceeded a certain threshold. </p> <p>We considered the measurement of the <sup>18</sup>F‐florbetaben retention (retention ratio): distribution volume ratio (DVR), standardised uptake value ratio (SUVR), or other ratios. DVR refers to the ratio of the <sup>18</sup>F‐florbetaben distribution volume in the selected area (ROI) to the distribution volume in the reference area. SUVR is the ratio of the <sup>18</sup>F‐florbetaben ligand standardised uptake value in the selected area (ROI) to the standardised uptake value in the reference area. </p> <p>The unit of analysis of our SR was the participant. We did not include studies that analysed multiple ROIs per person. </p> <p>Image analysis was not prespecified (e.g. Statistical Parametric Mapping (SPM) or other image analysis techniques). </p> <p><b>Administration Instructions and Recommended Dosing</b> </p> <p> <ul id="CD012883-list-0004"> <li> <p>Time between <sup>18</sup>F‐florbetaben injection and PET acquisition: images should be acquired in 15 to 20 minutes starting from 45 to 130 minutes after intravenous administration (<a href="./references#CD012883-bbs2-0033" title="Food , DrugAdministration . Neuroceq. www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf (accessed 08/04/2015). ">FDA 2014</a>) or acquired in 20 minutes starting from 90 minutes after intravenous administration (<a href="./references#CD012883-bbs2-0030" title="European Medicines Agency. Neuraceq. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002553/WC500162592.pdf (accessed 8th April 2015). ">EMA 2014</a>); </p> </li> </ul> <ul id="CD012883-list-0005"> <li> <p>Injection dose: the recommended dose for <sup>18</sup>F‐florbetaben Aβ PET is 300 MBq (8.1 mCi), maximum 30 mcg mass dose (<a href="./references#CD012883-bbs2-0033" title="Food , DrugAdministration . Neuroceq. www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf (accessed 08/04/2015). ">FDA 2014</a>) or 300 MBq (240 to 360 MBq) as a single slow intravenous bolus (6 sec/mL) in a total volume of up to 10 mL (<a href="./references#CD012883-bbs2-0030" title="European Medicines Agency. Neuraceq. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002553/WC500162592.pdf (accessed 8th April 2015). ">EMA 2014</a>). </p> </li> </ul> </p> <p>Although it was inevitable that included studies had used different imaging protocols, readers' expertise, and varied parameters, the amyloid PET data in these included studies should be technically adequate and acquired at a fully qualified and certified facility. </p> </section> <section id="CD012883-sec-0026"> <h3 class="title" id="CD012883-sec-0026">Clinical pathway</h3> <p>At this time, the clinical evaluation often has similarities between different countries (<a href="./references#CD012883-bbs2-0021" title="CordellaCB , BorsonS , BoustaniM , ChodoshJ , ReubenD , VergheseJ , et al. Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimer's &amp; Dementia2013;9(2):141‐50. ">Cordella 2013</a>; <a href="./references#CD012883-bbs2-0067" title="National Institute for Health Care Excellence. Dementia: supporting people with dementia and their carers in health and social care. NICE guidelines [CG42]. www.nice.org.uk/guidance/cg42 (accessed 17th April 2015). ">NICE 2006</a>). It often starts with people experiencing memory complaints detected by themselves or their relatives. Frequently, general practitioners or family physicians are consulted, and they often conduct a medical evaluation using a screening test for cognitive impairment. Whenever this screening test is positive, they complete an assessment with a clinical evaluation conducted with laboratory studies that can rule out a secondary cause of cognitive impairment (e.g. hypothyroidism, renal failure, liver failure, vitamin B12 or folate deficiency, and others). In addition, these people are then referred to medical specialists in cognitive disorders (preferably a geriatrician, psychiatrist, or neurologist) in a secondary centre or directly to memory clinics where further clinical assessment, laboratory studies, and cerebral image studies are conducted to confirm the dementia diagnosis. </p> <p>People with dementia, or their relatives, often directly consult these specialists or specialised memory clinics in the study of cognitive disorders. Therefore, the performance of the diagnostic tests will probably vary according to whether it is a primary consultation or referral from primary to specialist care, or if the people have different clinical stages of the disease (MCI, mild, moderate, or severe dementia). Due to these differing pathways, the use of <sup>18</sup>F‐florbetaben PET ligand for Aβ is mainly used in specialist consultations and memory clinics as an addition to clinical evaluation or other tests, helping in a clinical setting to discard a diagnosis of Alzheimer's dementia with a negative scan in a person with clinical dementia and doubts about the aetiology (e.g. FTD versus ADD). Otherwise, it might be used solely in the research field in people with MCI for the enrichment of clinical trials, for example, enrolling people with MCI and a positive PET scan to study preventive interventions before people develop dementia. </p> <p>However, in some memory clinics the <sup>18</sup>F‐florbetaben PET is used for clinical purposes in people with persistent or progressive unexplained MCI adopting the Johnson criteria (<a href="./references#CD012883-bbs2-0048" title="JohnsonKA , MinoshimaS , BohnenNI , DonohoeKJ , FosterNL , HerscovitchP , et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Journal of Nuclear Medicine2013;54(3):476‐90. ">Johnson 2013</a>), criteria without sufficient evidence. Therefore, if the <sup>18</sup>F‐florbetaben PET is positive in a person with MCI, this positivity is considered as one of the core histopathological findings of Alzheimer's disease. The person will thus be catalogued as a patient with prodromal Alzheimer's disease or MCI due to Alzheimer's disease. </p> <section id="CD012883-sec-0027"> <h4 class="title">Alternative test(s)</h4> <p>Currently, there are no standard practice tests available for the clinical diagnosis of Alzheimer's disease dementia. Below, we have listed the alternative tests that we have excluded from this SR. The Cochrane Dementia and Cognitive Improvement Group is in the process of conducting a series of DTA SRs of biomarkers and scales (see list below). </p> <p> <ul id="CD012883-list-0006"> <li> <p><sup>18</sup>F PET ligands for Aβ (<sup>18</sup>F‐florbetapir, <sup>18</sup>F‐flutemetamol) (<a href="./references#CD012883-bbs2-0055" title="MartínezG , FlickerL , VernooijRWM , Fuentes PadillaP , ZamoraJ , FigulsMRI , et al. 18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD012216] ">Martínez 2016</a>). </p> </li> </ul> <ul id="CD012883-list-0007"> <li> <p><sup>18</sup>F‐FDG‐PET (PET F‐fluorodeoxyglucose) (<a href="./references#CD012883-bbs2-0090" title="SmailagicN , VacanteM , HydeC , MartinS , UkoumunneO , SachpekidisC . 18F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2015, Issue 1. [DOI: 10.1002/14651858.CD010632.pub2] ">Smailagic 2015</a>). </p> </li> <li> <p>11C‐PIB‐PET (PET‐Pittsburgh compound B) (<a href="./references#CD012883-bbs2-0099" title="ZhangS , SmailagicN , HydeC , Noel‐StorrAH , TakwoingiY , McShaneR , et al. 11C‐PIB‐PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD010386.pub2] ">Zhang 2014</a>). </p> </li> <li> <p>Cerebrospinal fluid (CSF) analysis of Aβ and tau (<a href="./references#CD012883-bbs2-0050" title="KokkinouM , SmailagicN , Noel‐StorrAH , HydeC , UkoumunneO , WorrallRE , et al. Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD010945] ">Kokkinou 2014</a>; <a href="./references#CD012883-bbs2-0078" title="RitchieC , SmailagicN , LaddsEC , Noel‐StorrAH , UkoumunneO , MartinS . CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2013, Issue 10. [DOI: 10.1002/14651858.CD010803] ">Ritchie 2013</a>; <a href="./references#CD012883-bbs2-0079" title="RitchieC , SmailagicN , Noel‐StorrAH , TakwoingiY , FlickerL , MasonSE , et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2014, Issue 6. [DOI: 10.1002/14651858.CD008782.pub4] ">Ritchie 2014</a>). </p> </li> <li> <p>Structural magnetic resonance imaging (sMRI) (<a href="./references#CD012883-bbs2-0034" title="FilippiniG , CasazzaG , BellatorreAG , ListaC , DucaP , BeecherD , et al. The role of MRI in the early diagnosis of Alzheimer’s disease or other dementias in persons with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD009628] ">Filippini 2012</a>). </p> </li> <li> <p>Neuropsychological tests (Mini‐Mental State Examination (MMSE); MiniCOG; Montreal Cognitive Assessment (MoCA) (<a href="./references#CD012883-bbs2-0013" title="Arevalo‐RodriguezI , SmailagicN , FigulsMRI , CiapponiA , Sanchez‐PerezE , GiannakouA , et al. Mini‐Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD010783.pub2] ">Arevalo‐Rodriguez 2015</a>; <a href="./references#CD012883-bbs2-0019" title="ChanCCH , FageBA , SmailagicN , GillSS , HerrmannN , NikolaouV , et al. Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care setting. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD011414] ">Chan 2014</a>; <a href="./references#CD012883-bbs2-0022" title="CreavinS , WisniewskiS , Noel‐StorrA , TrevelyanC , HamptonT , RaymentD , et al. Mini‐Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD011145.pub2] ">Creavin 2016</a>; <a href="./references#CD012883-bbs2-0024" title="DavisDHJ , CreavinST , YipJLY , Noel‐StorrAH , BrayneC , CullumS . Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementias. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD010775.pub2] ">Davis 2015</a>; <a href="./references#CD012883-bbs2-0032" title="FageBA , ChanCCH , GillSS , Noel‐StorrAH , HerrmannN , SmailagicN , et al. Mini‐Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting. Cochrane Database of Systematic Reviews2015, Issue 2. [DOI: 10.1002/14651858.CD010860.pub2] ">Fage 2015</a>; <a href="./references#CD012883-bbs2-0087" title="SeitzDP , FageBA , ChanCCH , GillSS , HerrmannN , SmailagicN , et al. Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a primary care setting. Cochrane Database of Systematic Reviews2014, Issue 12. [DOI: 10.1002/14651858.CD011415] ">Seitz 2014</a>). </p> </li> <li> <p>Informant interviews (Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE); AD8) (<a href="./references#CD012883-bbs2-0038" title="HarrisonJK , FearonP , Noel‐StorrAH , McShaneR , StottDJ , QuinnTJ . Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) setting. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD010771.pub2] ">Harrison 2014</a>; <a href="./references#CD012883-bbs2-0041" title="HendryK , LeesRA , McShaneR , Noel‐StorrAH , StottDJ , QuinnTJ . AD‐8 for diagnosis of dementia across a variety of healthcare settings. Cochrane Database of Systematic Reviews2014, Issue 5. [DOI: 10.1002/14651858.CD011121] ">Hendry 2014</a>; <a href="./references#CD012883-bbs2-0051" title="LeesRA , StottDJ , McShaneR , Noel‐StorrAH , QuinnTJ . Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD011333] ">Lees 2014</a>; <a href="./references#CD012883-bbs2-0039" title="HarrisonJK , FearonP , Noel‐StorrAH , McShaneR , StottDJ , QuinnTJ . Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care setting. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD010772.pub2] ">Harrison 2015</a>; <a href="./references#CD012883-bbs2-0074" title="QuinnTJ , FearonP , Noel‐StorrAH , YoungC , McShaneR , StottDJ . Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations. Cochrane Database of Systematic Reviews2014, Issue 4. [DOI: 10.1002/14651858.CD010079.pub2] ">Quinn 2014</a>). </p> </li> <li> <p>APOE‐ϵ4 (<a href="./references#CD012883-bbs2-0027" title="Elias‐SonnenscheinLS , ViechtbauerW , RamakersI , UkoumunneO , VerheyFRJ , VisserPJ . APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a community setting. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD010948] ">Elias‐Sonnenschein 2014a</a>; <a href="./references#CD012883-bbs2-0028" title="Elias‐SonnenscheinLS , ViechtbauerW , RamakersI , UkoumunneO , VerheyFRJ , VisserPJ . APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a primary care setting. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD010949] ">Elias‐Sonnenschein 2014b</a>; <a href="./references#CD012883-bbs2-0029" title="Elias‐SonnenscheinLS , ViechtbauerW , RamakersI , UkoumunneO , VerheyFRJ , VisserPJ . APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a secondary care setting. Cochrane Database of Systematic Reviews2014, Issue 1. [DOI: 10.1002/14651858.CD010950] ">Elias‐Sonnenschein 2014c</a>). </p> </li> <li> <p>Single‐photon emission computed tomography (SPECT) brain imaging (<a href="./references#CD012883-bbs2-0012" title="ArcherHA , SmailagicN , JohnC , HolmesRB , TakwoingiY , CoulthardEJ , et al. Regional Cerebral Blood Flow Single Photon Emission Computed Tomography for detection of Frontotemporal dementia in people with suspected dementia. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD010896.pub2] ">Archer 2015</a>; <a href="./references#CD012883-bbs2-0058" title="McCleeryJ , MorganS , BradleyKM , Noel‐StorrAH , AnsorgeO , HydeC . Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. Cochrane Database of Systematic Reviews2015, Issue 1. [DOI: 10.1002/14651858.CD010633.pub2] ">McCleery 2015</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012883-sec-0028"> <h3 class="title" id="CD012883-sec-0028">Rationale</h3> <p>Accurate and early diagnosis of Alzheimer's disease is crucial for planning in healthcare systems, because the costs of dementia are currently at least 1% of the world's GNP (<a href="./references#CD012883-bbs2-0096" title="World Health Organization, Alzheimer's Disease International. Dementia: a public health priority. www.who.int/mental_health/publications/dementia_report_2012/en/ (accessed 23th September 2015). ">WHO 2012</a>). </p> <p><sup>18</sup>F‐florbetaben is approved for use in the clinical field mainly in people who are diagnosed clinically with dementia of uncertain aetiology, in which case diagnosis of ADD can be discarded if the test is negative. Even though <sup>18</sup>F‐florbetaben is not approved for this purpose, this biomarker test is currently being used in the research field to search for the accurate identification of people with MCI who would progress to ADD or other forms of dementia. Amyloid β tracers by PET have been included in newly diagnostic criteria in the study in people with MCI (<a href="./references#CD012883-bbs2-0008" title="AlbertMS , DeKoskyST , DicksonD , DuboisB , FeldmanHH , FoxNC , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(3):270‐9. ">Albert 2011</a>; <a href="./references#CD012883-bbs2-0026" title="DuboisB , FeldmanHH , JacovaC , HampelH , MolinuevoJL , BlennowK , et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG‐2 criteria. Lancet. Neurology2014;13(6):614‐29. ">Dubois 2014</a>). However, some uncertainties exist about the generalisability of the DTA results in clinical settings, especially in older people (<a href="./references#CD012883-bbs2-0077" title="RichardE , SchmandB , EikelenboomP , WestendorpRG , VanGoolWA . The Alzheimer myth and biomarker research in dementia. Journal of Alzheimer's Disease2012;31(Suppl 3):S203‐9. ">Richard 2012</a>). </p> <p>It is currently believed that if the health system can identify which people are at high risk of progressing from MCI to dementia, it can focus on improving opportunities for appropriate contingency planning for them. Proper recognition of the disease may also help prevent inappropriate and potentially harmful admissions to hospital or institutional care (<a href="./references#CD012883-bbs2-0065" title="National Audit Office. Improving services and support for people with dementia. Report by the Comptroller and Auditor General. HC 604 Session General 2006‐2007. www.nao.org.uk/wp‐content/uploads/2007/07/0607604.pdf (accessed 25th March 2015). ">NAO 2007</a>), and enable the development of new treatments designed to delay or prevent progression to more debilitating stages of the disease. Additionally, this may demonstrate a real clinical benefit for people and caregivers, and will reduce health system costs. </p> <p>This SR assesses the DTA with <sup>18</sup>F‐florbetaben Aβ PET in people with MCI. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012883-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012883-sec-0029"></div> <p>To determine the diagnostic test accuracy (DTA) of <sup>18</sup>F‐florbetaben as the index test for detecting people with mild cognitive impairment (MCI) at time of performing the test who would clinically progress to Alzheimer's disease dementia (ADD), or other forms of non‐ADD, or any form of dementia at follow‐up. </p> <section id="CD012883-sec-0030"> <h3 class="title" id="CD012883-sec-0030">Secondary objectives</h3> <p>To investigate the heterogeneity of the DTA in the included studies, by evaluating the spectrum of people, referral centres, clinical criteria of MCI, <sup>18</sup>F‐florbetaben techniques, reference standards used, duration of follow‐up, aspects of study quality, and conflicts of interest. </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012883-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012883-sec-0031"></div> <section id="CD012883-sec-0032"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012883-sec-0033"> <h4 class="title">Types of studies</h4> <p>We included longitudinal studies that had prospectively defined cohorts with any accepted definition of mild cognitive impairment (MCI), as outlined below, at time of performing the <sup>18</sup>F‐florbetaben Aβ scan and a reference standard (see <a href="#CD012883-sec-0035">Index tests</a> and <a href="#CD012883-sec-0037">Reference standards</a> below). We obtained the results at the follow‐up of the studies. These studies had to employ delayed verification of progression to dementia and were sometimes labelled as 'delayed verification cross‐sectional studies' (<a href="./references#CD012883-bbs2-0015" title="BossuytPM , LeeflangMM . Chapter 6: Developing criteria for including studies. In: Deeks JJ, Bossuyt PM, Gatsonis C, editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2013. Available from srdta.cochrane.org. ">Bossuyt 2008</a>; <a href="./references#CD012883-bbs2-0049" title="KnottnerusJA , VanWeelC , MurisJW . Evaluation of diagnostic procedures. BMJ2002;324(7335):477‐80. ">Knottnerus 2002</a>). We included case‐control studies when they incorporate a delayed verification design. This occurred in the context of a cohort study, so these studies were invariably diagnostic‐nested case‐control studies. </p> </section> <section id="CD012883-sec-0034"> <h4 class="title">Participants</h4> <p>Participants recruited and clinically classified as having MCI at time of performing the test were eligible for inclusion. We established the diagnosis of MCI using the Petersen criteria or revised Petersen criteria (<a href="./references#CD012883-bbs2-0071" title="PetersenRC , SmithGE , WaringSC , IvnikRJ , TangalosEG , KokmenE . Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology1999;56(3):303‐8. ">Petersen 1999</a>; <a href="./references#CD012883-bbs2-0072" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004;256(3):183‐94. ">Petersen 2004</a>; <a href="./references#CD012883-bbs2-0097" title="WinbladB , PalmerK , KivipeltoM , JelicV , FratiglioniL , WahlundLO , et al. Mild cognitive impairment ‐ beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine2004;256(3):240‐6. ">Winblad 2004</a>), the criteria included in Matthews study (<a href="./references#CD012883-bbs2-0056" title="MatthewsFE , StephanBC , McKeithIG , BondJ , BrayneC , Medical Research Council Cognitive Function and Ageing Study. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society2008;56(8):1424‐33. ">Matthews 2008</a>), CDR = 0.5 (CDR structured interviews collects information from both the collateral source and the subject regarding memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care, where the range of possible scores varies from none = 0 point to severe = 3 points) (<a href="./references#CD012883-bbs2-0064" title="MorrisJC . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology1993;43(11):2412‐4. ">Morris 1993</a>), the National Institute on Aging‐Alzheimer's Association (NIA‐AA) core clinical criteria (<a href="./references#CD012883-bbs2-0008" title="AlbertMS , DeKoskyST , DicksonD , DuboisB , FeldmanHH , FoxNC , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7(3):270‐9. ">Albert 2011</a>), or a combination. </p> <p>We excluded studies that included people with MCI possibly caused by any of the following.</p> <p> <ul id="CD012883-list-0008"> <li> <p>Current or a history of alcohol or drug abuse.</p> </li> <li> <p>Central nervous system (CNS) trauma (e.g. subdural hematoma), tumour, or infection.</p> </li> <li> <p>Other neurological conditions (e.g. Parkinson’s or Huntington’s diseases). Regarding Parkinson's disease, many of the studies specifically excluded people with Parkinson's disease from the group with mild cognitive impairment. This specific group of people is complex in both regards to defining neuropathology and in determination of functional decline. For these reasons, this group of people needs to be addressed in specific studies. </p> </li> </ul> </p> </section> <section id="CD012883-sec-0035"> <h4 class="title">Index tests</h4> <p>The index test of this SR was <sup>18</sup>F‐florbetaben biomarker test. We used the criteria and cut‐off values for test positivity, as reported in the included studies. We considered positivity for <sup>18</sup>F‐florbetaben Aβ scan uptake and retention exceeding a certain threshold. </p> </section> <section id="CD012883-sec-0036"> <h4 class="title">Target conditions</h4> <p>Three target conditions were included in this SR:</p> <p> <ul id="CD012883-list-0009"> <li> <p>Alzheimer’s disease dementia (ADD) (progression from MCI to ADD).</p> </li> <li> <p>Any other forms of dementia (progression from MCI to any other forms of non‐ADD).</p> </li> <li> <p>Any form of dementia (progression from MCI to any form of dementia).</p> </li> </ul> </p> </section> <section id="CD012883-sec-0037"> <h4 class="title">Reference standards</h4> <p>The reference standard was the progression to the target conditions evaluated by a physician with expertise in the dementia field (preferably a geriatrician, psychiatrist, or neurologist). For the purpose of this SR, we accepted several definitions of ADD. We included studies that applied the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDSADRDA) criteria (<a href="./references#CD012883-bbs2-0061" title="McKhannGM , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;34(7):939‐44. ">McKhann 1984</a>), the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria (<a href="./references#CD012883-bbs2-0010" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1987. ">APA 1987</a>; <a href="./references#CD012883-bbs2-0011" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>), and the International Classification of Diseases (ICD) (<a href="./references#CD012883-bbs2-0045" title="World Health Organization. International statistical Classification of Diseases and related health problems (ICD‐10 Version 2010). apps.who.int/classifications/icd10/browse/2010/en (accessed 29 January 2015). ">ICD‐10</a>) criteria for ADD. Notably, different iterations of these standards may not be directly comparable over time (e.g. <a href="./references#CD012883-bbs2-0010" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1987. ">APA 1987</a> versus <a href="./references#CD012883-bbs2-0011" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>). Moreover, the validity of the diagnoses may vary with the degree or manner in which the criteria have been operationalised (e.g. individual clinician versus algorithm versus consensus determination). We considered all these issues when we interpreted the results. </p> <p>Similarly, we accepted differing clinical definitions of other dementias. For Lewy body dementia, the reference standard is the McKeith criteria (<a href="./references#CD012883-bbs2-0059" title="McKeithIG , GalaskoD , KosakaK , PerryEK , DicksonDW , HansenLA , et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology1996;47(5):1113‐24. ">McKeith 1996</a>; <a href="./references#CD012883-bbs2-0060" title="McKeithIG , DicksonDW , LoweJ , EmreM , O'BrienJT , FeldmanH , et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology2005;65(12):1863‐72. ">McKeith 2005</a>); for frontotemporal dementia the Lund criteria (<a href="./references#CD012883-bbs2-0016" title="BoxerAL , MillerBL . Clinical features of frontotemporal dementia. Alzheimer Disease and Associated Disorders2005;19(Suppl 1):S3‐6. ">Boxer 2005</a>; <a href="./references#CD012883-bbs2-0017" title="BrunA , EnglundB , GustafsonL , PassantU , MannDMA , NearyD , et al. Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry1994;57(4):416‐8. ">Brun 1994</a>; <a href="./references#CD012883-bbs2-0066" title="NearyD , SnowdenJS , GustafsonL , PassantU , StussD , BlackS , et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology1998;51(6):1546‐54. ">Neary 1998</a>), the DSM criteria (<a href="./references#CD012883-bbs2-0010" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1987. ">APA 1987</a>; <a href="./references#CD012883-bbs2-0011" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>), the ICD criteria (<a href="./references#CD012883-bbs2-0045" title="World Health Organization. International statistical Classification of Diseases and related health problems (ICD‐10 Version 2010). apps.who.int/classifications/icd10/browse/2010/en (accessed 29 January 2015). ">ICD‐10</a>), or the International Behavioural Variant FTD Criteria Consortium (<a href="./references#CD012883-bbs2-0075" title="RascovskyK , HodgesJR , KnopmanD , MendezMF , KramerJH , NeuhausJ , et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain2011;134(Pt 9):2456‐77. ">Rascovsky 2011</a>); for vascular dementia, the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences (NINDS‐AIREN) criteria (<a href="./references#CD012883-bbs2-0080" title="RománGC , TatemichiTK , ErkinjunttiT , CummingsJL , MasdeuJC , GarciaJH , et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN International Workshop. Neurology1993;43(2):250‐60. ">Román 1993</a>), the DSM criteria (<a href="./references#CD012883-bbs2-0010" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1987. ">APA 1987</a>; <a href="./references#CD012883-bbs2-0011" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994. ">APA 1994</a>), or the ICD criteria (<a href="./references#CD012883-bbs2-0045" title="World Health Organization. International statistical Classification of Diseases and related health problems (ICD‐10 Version 2010). apps.who.int/classifications/icd10/browse/2010/en (accessed 29 January 2015). ">ICD‐10</a>); and, for progressive supranuclear palsy (PSP), the preliminary NINDS criteria (<a href="./references#CD012883-bbs2-0040" title="HauwJJ , DanielSE , DicksonD , HoroupianDS , JellingerK , LantosPL , et al. Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy). Neurology1994;44(11):2015‐9. ">Hauw 1994</a>). </p> <p>The time interval over which the progression from MCI to ADD (or other forms of dementia) occurs is very important. We used one year as the minimum period of delay in the verification of the diagnosis (the time between the assessment at which a diagnosis of MCI is made and the assessment at which the diagnosis of dementia is made). </p> </section> </section> <section id="CD012883-sec-0038"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012883-sec-0039"> <h4 class="title">Electronic searches</h4> <p>We searched MEDLINE (Ovid SP) from 1946 to May 2017; Embase (Ovid SP) from 1974 to May 2017; PsycINFO (Ovid SP) from 1806 to May 2017; BIOSIS Citation Index (Thomson Reuters Web of Science) from 1922 to May 2017; Web of Science Core Collection, including the Science Citation Index (Thomson Reuters Web of Science) and the Conference Proceedings Citation Index (Thomson Reuters Web of Science) from 1946 to May 2017; LILACS (Bireme); CINAHL (EBSCOhost) from 1980 to May 2017; ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">https://clinicaltrials.gov</a>); and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="http://www.who.int/ictrp/search/en/" target="_blank">http://www.who.int/ictrp/search/en/</a>). We also searched ALOIS, the Cochrane Dementia &amp; Cognitive Improvement Group’s specialized register of dementia studies (<a href="http://www.medicine.ox.ac.uk/alois/" target="_blank">http://www.medicine.ox.ac.uk/alois/</a>). </p> <p>We used two approaches in designing the search. One focused solely on the specifically named index test (including a range of synonyms) and the second, run in parallel covered a more general search, linking broader terms for the index test. It focused on terms describing its diagnostic use and terms for the target condition to try to capture the more difficult to locate studies of a more general nature, where these particular radioligands were included in diagnostic accuracy research but not named specifically in the parts of the electronic bibliographic record that are searchable and therefore would be missed. </p> <p>See <a href="./appendices#CD012883-sec-0066">Appendix 2</a> for details of the sources and search strategies that we used. No language or date restrictions were applied to the electronic searches. </p> </section> <section id="CD012883-sec-0040"> <h4 class="title">Searching other resources</h4> <p>We examined the reference lists of all relevant studies for additional studies. We also searched the Database of Abstracts of Reviews of Effects (DARE) via the Cochrane Library (<a href="http://www.cochranelibrary.com" target="_blank">www.cochranelibrary.com</a>)), the National Institute for Health Research ‐ Health Technology Assessment Database (NIHR‐HTA) (via the Cochrane Library: <a href="http://www.cochranelibrary.com" target="_blank">www.cochranelibrary.com</a>), the Aggressive Research Intelligence Facility (ARIF) database (<a href="http://www.arif.bham.ac.uk/" target="_blank">www.arif.bham.ac.uk</a>) for other related systematic diagnostic accuracy reviews, and the International Federation of Clinical Chemistry and Laboratory Medicine Committee for Evidence‐based Laboratory Medicine database (C‐EBLM) (<a href="http://www.ifcc.org/ifcc-education-division/emd-committees/c-eblm/evidence-based-laboratory-medicine-c-eblm-base" target="_blank">http://www.ifcc.org/ifcc‐education‐division/emd‐committees/c‐eblm/evidence‐based‐laboratory‐medicine‐c‐eblm‐base</a>). </p> <p>We checked the reference lists of any relevant studies and SRs, and performed citation tracking using the Science Citation Index to identify any additional relevant studies. </p> </section> </section> <section id="CD012883-sec-0041"> <h3 class="title" id="CD012883-sec-0041">Data collection and analysis</h3> <section id="CD012883-sec-0042"> <h4 class="title">Selection of studies</h4> <p>Two review authors (GM, RV) independently screened the retrieved titles and abstracts for potentially eligible studies. A third review author (PF) resolved any disagreements between the two review authors. The two review authors (GM, RV) then independently assessed the full‐text articles of the selected studies with the inclusion criteria. They resolved any disagreements through discussion or, where necessary, consulted a third review author (PF) who acted as an arbitrator. When a study did not present all relevant data for creating 2 × 2 table, we contacted the study authors directly to request further information. When more than one article presented data on the same population, we included the primary article, which was the article with the largest number of people or with the most informative data (e.g. longest time of follow‐up in the primary outcome). </p> </section> <section id="CD012883-sec-0043"> <h4 class="title">Data extraction and management</h4> <p>We planned to extract the following data regarding the study characteristics.</p> <p> <ul id="CD012883-list-0010"> <li> <p>Bibliographic details of primary paper:</p> <ul id="CD012883-list-0011"> <li> <p>author, title of study, year, and journal.</p> </li> </ul> </li> <li> <p>Basic clinical and demographic details:</p> <ul id="CD012883-list-0012"> <li> <p>number of participants;</p> </li> <li> <p>clinical diagnosis;</p> </li> <li> <p>MCI clinical criteria;</p> </li> <li> <p>age;</p> </li> <li> <p>gender;</p> </li> <li> <p>sources of referral;</p> </li> <li> <p>participant recruitment;</p> </li> <li> <p>sampling procedures.</p> </li> </ul> </li> <li> <p>Details of the index test:</p> <ul id="CD012883-list-0013"> <li> <p>method of the <sup>18</sup>F‐florbetaben administration, including those who administered the test; </p> </li> <li> <p>thresholds used to define positive and negative tests;</p> </li> <li> <p>other technical aspects as seemed relevant to the review, e.g. brain areas.</p> </li> </ul> </li> <li> <p>Details of the reference standard:</p> <ul id="CD012883-list-0014"> <li> <p>definition of ADD and other dementias used in the reference standard;</p> </li> <li> <p>duration of follow‐up from time of the index test performed to defining ADD and other dementias by the reference standard: one year to less than two years; two years to less than four years; and four years or more. If participants had been followed for varied amounts of time, we recorded a mean follow‐up period for each included study. If possible, we grouped those data into minimum, maximum, and median follow‐up periods, to enable subgroup analyses; </p> </li> <li> <p>prevalence or proportion of population developing ADD and other dementias, with severity, if described. </p> </li> </ul> </li> </ul> </p> <p>We created 2 × 2 tables (cross‐relating index test results of the reference standards) as shown in <a href="./appendices#CD012883-sec-0067">Appendix 3</a>. For the included study, we recorded the number of participants lost to follow‐up. We also extracted data necessary for the quality assessment, as defined below. Two review authors (GM, RV) independently performed data extraction. We resolved any disagreements regarding data extraction by discussion, or by consulting a third review author (PF), if it was necessary. </p> </section> <section id="CD012883-sec-0044"> <h4 class="title">Assessment of methodological quality</h4> <p>We assessed the methodological quality of the included studies using the Quality Assessment of Diagnostic Accuracy Studies 2 tool (QUADAS‐2) (<a href="./references#CD012883-bbs2-0095" title="WhitingPF , RutjesAWS , WestwoodME , MalletS , DeeksJJ , ReitsmaJB . QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529‐36. ">Whiting 2011</a>), as recommended by Cochrane (<a href="./references#CD012883-bbs2-0023" title="DavisDHJ , CreavinST , Noel‐StorrA , QuinnTJ , SmailagicN , HydeC , et al. Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross‐sectional and delayed‐verification studies. Cochrane Database of Systematic Reviews2013, Issue 3. [DOI: 10.1002/14651858.CD010460] ">Davis 2013</a>). This tool is comprised of four domains: patient selection, index test, reference standard, and patient flow.<br/> <br/> Two review authors (GM, RV), who were blinded to each other’s scores, independently performed the QUADAS‐2 assessment. We resolved any disagreements by discussion or, if necessary, consulted a third review author (PF) who acted as an arbitrator. We assessed each domain in terms of risk of bias, and also considered the first three domains in terms of applicability concerns. In <a href="./appendices#CD012883-sec-0068">Appendix 4</a>, we have detailed the components of each of these domains and provided a rubric that shows how we made judgements concerning risk of bias. Key areas important to quality assessment were participant selection, blinding, and missing data. </p> <p>We included three additional signalling questions on our checklist.</p> <p> <ul id="CD012883-list-0015"> <li> <p>Was the PET scan interpretation done by a trained reader physician? (We included this under the ’Index test’ domain.) </p> </li> <li> <p>Was there a clear definition of a positive result? (We included this under the ’Index test’ domain.) </p> </li> <li> <p>Was the study free of commercial funding? (We included this under the ’flow and timing’ domain.) </p> </li> </ul> </p> <p>We included the item pertaining to the PET scan interpretation and the definition of positive results to take into account the subjective nature of the <sup>18</sup>F‐florbetaben Aβ scan image interpretation, which may be based on a variety of different criteria, such as extensive clinical experience, different standardised uptake values (SUV), different morphological features, or a combination of the aforementioned. We included the third additional item in order to record any potential bias resulting from commercial interest in the results due to the potential risk by the manufacturing company leading to more favourable results and conclusions than sponsorship by other sources (<a href="./references#CD012883-bbs2-0053" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2017</a>). </p> <p>We did not use QUADAS‐2 data to form a summary quality score. We produced a narrative summary that described each included study as at high, low, or unclear risk of bias, as well as concerns regarding applicability, which we have described in <a href="./appendices#CD012883-sec-0069">Appendix 5</a>. </p> </section> <section id="CD012883-sec-0045"> <h4 class="title">Statistical analysis and data synthesis</h4> <p>We applied the DTA framework for the analysis of a single test and extracted the data from the study into a 2 x 2 table, showing the binary test results cross‐classified with the binary reference standard. We used data from the 2 x 2 tables abstracted from the included study: true positive (TP), false negative (FN), false positive (FP), true negative (TN), and entered these into Review Manager (RevMan) <a href="./references#CD012883-bbs2-0076" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a> to calculate the sensitivities, specificities, and their 95% confidence intervals. We also presented the study results graphically by plotting estimates of sensitivities and specificities in a forest plot. </p> <p>However, due to lack of data, we conducted no meta‐analyses. However, we prepared a 'summary of findings table'. </p> </section> <section id="CD012883-sec-0046"> <h4 class="title">Investigations of heterogeneity</h4> <p>We were able to include only one study, therefore issues of heterogeneity did not arise. </p> </section> <section id="CD012883-sec-0047"> <h4 class="title">Sensitivity analyses</h4> <p>We found insufficient data to conduct any sensitivity analyses.</p> </section> <section id="CD012883-sec-0048"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not investigate reporting bias.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012883-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012883-sec-0049"></div> <section id="CD012883-sec-0050"> <h3 class="title" id="CD012883-sec-0050">Results of the search</h3> <p>The total number of records identified through all databases for this SR was 1382. The PRISMA diagram shows the selection of records through the screening and selection processes (<a href="#CD012883-fig-0001">Figure 1</a>). In total, we assessed 79 studies (42 full text papers, 16 conference publications, 9 registered studies in clinicaltrials.gov, and 12 registered in WHO ICTRP) for eligibility in the full‐text screening. We included one study (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). Additionally, five references were identified as ongoing studies (<a href="./references#CD012883-bbs2-0003" title="EUCTR2013‐004671‐12‐BE . Predictive value of biomarkers in patients with amnestic mild cognitive impairment. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013‐004671‐12‐BE (first received 20 May 2014). ">EUCTR2013‐004671‐12‐BE</a>; <a href="./references#CD012883-bbs2-0004" title="EUCTR2014‐000562‐21‐NL . Amyloid‐PET as a diagnostic marker in daily practice. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐000562‐21‐NL (first received 5 January 2015). ">EUCTR2014‐000562‐21‐NL</a>; <a href="./references#CD012883-bbs2-0005" title="EUCTR2014‐004244‐35‐IT . Amyloid load in prodromal AD with limbic‐predominant phenotype [Amyloid load in prodromal AD with limbic‐predominant phenotype principal investigator ‐ Studio del Carico di Amiloide in AD prodromico con fenotipo limbico]. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐004244‐35‐IT (first received 13 November 2014). ">EUCTR2014‐004244‐35‐IT</a>; <a href="./references#CD012883-bbs2-0006" title="NCT01222351 . Measuring brain amyloid plaque load in older adults using BAY 94‐9172. clinicaltrials.gov/show/NCT01222351 (first received 18 October 2010). ">NCT01222351</a>, <a href="./references#CD012883-bbs2-0007" title="NCT02854033 . Alzheimer's disease neuroimaging initiative 3 (ADNI3) protocol. clinicaltrials.gov/show/NCT02854033 (first received 3 August 2016). ">NCT02854033</a>). We excluded 73 studies: 19 studies were multiple publications or duplicated, and the remaining 53 studies were excluded as they did not meet the inclusion criteria: i) not a longitudinal study (n = 13); ii) not MCI participants at baseline (n = 14); iii) index test not a <sup>18</sup>F‐florbetaben PET scan (n = 5); iv) discussion or review paper (n = 19); v) wrong outcome or study design (n = 2). One study did not have data suitable for analysis (<a href="./references#CD012883-sec-0079" title="">Characteristics of excluded studies</a>). </p> <div class="figure" id="CD012883-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram." data-id="CD012883-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> </div> <section id="CD012883-sec-0051"> <h4 class="title">Included Study</h4> <p>See <a href="./references#CD012883-sec-0078" title="">Characteristics of included studies</a>. </p> <p>The study of Ong 2015 was conducted in Australia (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). This study included older adult participants who were referred from local memory clinics and who met consensus criteria for MCI at baseline, and were recruited as part of a study to evaluate the <sup>18</sup>F‐florbetaben PET positivity scan at baseline and progression from MCI to ADD, and compare an SUVR assessment with visually assessed scans in determining a positive or negative scan. The other objective of this study was to examine whether progressive Aβ accumulation was detectable using the <sup>18</sup>F‐florbetaben PET scan at follow‐up. </p> <p>Ong 2015 included 45 MCI participants and performed follow‐up at two and four years, evaluating progression from MCI to probable ADD. The authors described their <sup>18</sup>F‐florbetaben status as positive or negative, using a visual assessment by five readers trained on an electronic training tool and their SUVR &gt; 1.45 as described previously (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). We included the data at four years of follow‐up, because, according to the methodology, we included the longest time of follow‐up in the primary outcome. MCI participants fulfilled the <a href="./references#CD012883-bbs2-0072" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004;256(3):183‐94. ">Petersen 2004</a> and <a href="./references#CD012883-bbs2-0097" title="WinbladB , PalmerK , KivipeltoM , JelicV , FratiglioniL , WahlundLO , et al. Mild cognitive impairment ‐ beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine2004;256(3):240‐6. ">Winblad 2004</a> criteria for MCI. Participants had to be at least 60 years old and to have had at least seven years of formal schooling. They were also required to communicate fluently in English, to have no contraindications to undergoing an MRI scan, and to have a MMSE of &gt; 23 points. </p> <p>There were 21 participants with <sup>18</sup>F‐florbetaben with an SUVR value &lt; 1.45 and 24 participants with a <sup>18</sup>F‐florbetaben SUVR value &gt; 1.45; using the visual assessment, there were 20 participants with <sup>18</sup>F‐florbetaben negative and 25 participants with <sup>18</sup>F‐florbetaben positive. The demographic data provided was based on those classified as positive or negative by SUVR. The age of the participants was 71.8 + 6.1 and 73.5 + 6.9 years, years of education 13.5 + 3.0, and 13.8 + 4.2, and MMSE was 27.9 + 1.4 and 26.7 + 1.9 for those with <sup>18</sup>F‐florbetaben &lt; 1.45 or &gt; 1.45, respectively. No demographic data was available for those classified by visual assessment. Of the 45 participants classified with SUVR, at four years follow‐up, 21 of 45 participants (46.7%) had developed ADD, and 5 of 45 (11.1%) had developed another form of dementia. Of the 45 participants classified with visual assessment, at four years follow‐up, 21 of 45 participants (46.7%) had developed ADD, and 5 of 45 (11.1%) had developed another form of dementia. At four years follow‐up, the diagnosis was performed by a neurologist with access to all study results and personal medical records. The reference standard was the NINCDS‐ADRDA criteria for ADD (<a href="./references#CD012883-bbs2-0061" title="McKhannGM , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;34(7):939‐44. ">McKhann 1984</a>) and, for other forms of dementia, the reference standards were <a href="./references#CD012883-bbs2-0059" title="McKeithIG , GalaskoD , KosakaK , PerryEK , DicksonDW , HansenLA , et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology1996;47(5):1113‐24. ">McKeith 1996</a> for Lewy body dementia, Lund criteria for frontotemporal dementia <a href="./references#CD012883-bbs2-0066" title="NearyD , SnowdenJS , GustafsonL , PassantU , StussD , BlackS , et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology1998;51(6):1546‐54. ">Neary 1998</a>, and <a href="./references#CD012883-bbs2-0040" title="HauwJJ , DanielSE , DicksonD , HoroupianDS , JellingerK , LantosPL , et al. Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy). Neurology1994;44(11):2015‐9. ">Hauw 1994</a> for PSP. </p> <p>Potential conflicts of interest were noted. Financial support for the study was provided by the previous and current manufacturer of the test; three authors were employees from the previous manufacturer of <sup>18</sup>F‐florbetaben tracer and another three authors were employees from the actual manufacturer of <sup>18</sup>F‐florbetaben (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). </p> </section> <section id="CD012883-sec-0052"> <h4 class="title">Ongoing studies</h4> <p>Two studies were found as ongoing studies in clinicaltrials.gov. The first study, <a href="./references#CD012883-bbs2-0006" title="NCT01222351 . Measuring brain amyloid plaque load in older adults using BAY 94‐9172. clinicaltrials.gov/show/NCT01222351 (first received 18 October 2010). ">NCT01222351</a>, included a sub‐study of the Washington Heights‐Inwood Community Aging Project focused on cognitively normal older adults, older adults with MCI, and older adults with Alzheimer's disease. Participants were selected on the basis of change in plasma amyloid beta levels over prior assessment intervals. The purpose of the study was to examine whether brain amyloid plaque load, which was to be measured with <sup>18</sup>F‐florbetaben PET scan, varied as a function of change in plasma levels of amyloid beta and the risk and progression of late onset Alzheimer's disease, MCI, and cognitive decline after three years follow‐up. No further details were provided regarding index test and reference standard(s). This study has been recruiting participants since December 2010 in the United States. No expected date of publication was provided in this record. The second study, <a href="https://clinicaltrials.gov/show/NCT02854033" target="_blank">NCT02854033</a>, was focused on cognitively normal, mild cognitive impairment, and mild ADD participants. The main objective was to determine the relationships among the clinical, cognitive, imaging, genetic, and biochemical biomarker characteristics and the evolution of the entire spectrum of ADD and try to identify diagnostic and prognostic markers among others. The clinical follow‐up will be five years. No further details were provided regarding the reference standard(s). This study has been recruiting participants since October 2016. No expected date of publication was provided in this record. </p> <p>Three studies were found as ongoing studies in WHO ICTRP and they belong to the European Union Clinical Trials Register. <a href="./references#CD012883-bbs2-0005" title="EUCTR2014‐004244‐35‐IT . Amyloid load in prodromal AD with limbic‐predominant phenotype [Amyloid load in prodromal AD with limbic‐predominant phenotype principal investigator ‐ Studio del Carico di Amiloide in AD prodromico con fenotipo limbico]. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐004244‐35‐IT (first received 13 November 2014). ">EUCTR2014‐004244‐35‐IT</a> is a study focused on amnestic MCI participants with long disease duration (range 2 to 10 years) and imaging studies (MRI and/or <sup>18</sup>F‐FDG‐PET) suggestive of involvement of the limbic/mesial temporal lobe, with the main objective to define the value of the load of amyloid protein. The secondary outcome was the correlation of the amyloid load with neuropsychological measures, the clinical indices, the values of Aβ42, total tau, and phospho‐tau and with data from MRI and <sup>18</sup>F‐FDG‐PET previously acquired for diagnostic purposes and with a clinical follow‐up for at least two years in order to assess the possible clinical progression with basal <sup>18</sup>F‐florbetaben. No further details were provided regarding the participants, index test, and reference standard(s). This study has been ongoing since March 2015. No expected date of publication was provided in this record. </p> <p>One additional Dutch ongoing study has been found that focuses on an unselected patient population of subjects visiting the memory clinic of the VUmc Alzheimer Center (<a href="./references#CD012883-bbs2-0004" title="EUCTR2014‐000562‐21‐NL . Amyloid‐PET as a diagnostic marker in daily practice. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2014‐000562‐21‐NL (first received 5 January 2015). ">EUCTR2014‐000562‐21‐NL</a>). Its main objective was change after <sup>18</sup>F‐florbetaben in diagnosis, change in level of confidence of diagnosis, and the impact on patient healthcare management, and the secondary outcome in those with MCI was the clinical progression to dementia during annual follow‐up (based on follow‐up visits to neurologist and neuropsychologist). No further details were provided regarding the participants, index test, and reference standard(s) and the length of follow‐up. This study has been ongoing since January 2015. Similarly, no expected date of publication was provided in this record. </p> <p>One additional Belgian ongoing study has been found that focuses on the predictive value of baseline <sup>18</sup>F‐florbetaben capture for longitudinal change in amyloid load measured using PET in MCI cases (<a href="./references#CD012883-bbs2-0003" title="EUCTR2013‐004671‐12‐BE . Predictive value of biomarkers in patients with amnestic mild cognitive impairment. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2013‐004671‐12‐BE (first received 20 May 2014). ">EUCTR2013‐004671‐12‐BE</a>). A secondary outcome was the comparison of CSF Aß42 and amyloid PET for classification of amyloid‐positive and amyloid‐negative cases, and the comparison of the predictive value of CSF biomarkers Aß42, T‐tau and P‐tau181P with that of amyloid imaging for MCI cases that progressed to Alzheimer's disease dementia. No further details were provided regarding the index test, and reference standard(s). This study has been ongoing since June 2014 and no expected date of publication has been provided. </p> </section> </section> <section id="CD012883-sec-0053"> <h3 class="title">Methodological quality of included studies</h3> <p>We assessed methodological quality using the QUADAS‐2 tool (<a href="./references#CD012883-bbs2-0095" title="WhitingPF , RutjesAWS , WestwoodME , MalletS , DeeksJJ , ReitsmaJB . QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529‐36. ">Whiting 2011</a>). Review authors’ judgements about each methodological quality item for the included study are presented in the <a href="./references#CD012883-sec-0078" title="">Characteristics of included studies</a> and in <a href="#CD012883-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD012883-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012883-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> </div> <p>In the patient selection domain, we considered the study of Ong 2015 to be at unclear risk of bias due to lack of reporting on sampling procedures and exclusion criteria (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). We stated that the included study avoided a case‐control design because we only considered data on performance of the index test to discriminate between people with MCI who converted to dementia and those who remained stable. </p> <p>In the index test domain, we considered the study of Ong 2015 at low risk of bias because the positive threshold used in both visual and quantitative assessment was prespecified (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). Moreover, the index test results were interpreted without knowledge of the results of the reference standard. In our two additional signalling questions, the risk concerning the index test being interpreted by a trained reader physician was low, because they were trained on an electronic training tool to do the amyloid PET visual interpretation. The other signalling question was rated as low risk, because there was a clear definition of a positive result. </p> <p>In the reference standard domain, we considered the study to be at high risk of bias because it was reported that the neurologist had access to all study results and personal medical records to make the diagnosis (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). However, the reference standard(s) were clearly established (<a href="./references#CD012883-bbs2-0061" title="McKhannGM , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;34(7):939‐44. ">McKhann 1984</a>, <a href="./references#CD012883-bbs2-0059" title="McKeithIG , GalaskoD , KosakaK , PerryEK , DicksonDW , HansenLA , et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology1996;47(5):1113‐24. ">McKeith 1996</a><a href="./references#CD012883-bbs2-0066" title="NearyD , SnowdenJS , GustafsonL , PassantU , StussD , BlackS , et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology1998;51(6):1546‐54. ">Neary 1998</a>; <a href="./references#CD012883-bbs2-0040" title="HauwJJ , DanielSE , DicksonD , HoroupianDS , JellingerK , LantosPL , et al. Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy). Neurology1994;44(11):2015‐9. ">Hauw 1994</a>). </p> <p>In the flow and timing domain, we judged the study to be at high risk of bias because in our additional signalling question there were potential conflicts of interest due to the financial support for the study and, in addition, three authors were employees of the previous manufacturer of <sup>18</sup>F‐florbetaben tracer and the other three authors were employees of the actual manufacturer of <sup>18</sup>F‐florbetaben (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). However, the four years of interval between the index test and the reference standard was considered an appropriate interval, all participants received the same reference standard(s), and all 45 participants were accounted for in the analysis. </p> <p>For assessment of applicability, there was no concern that the included patients and setting, and the conduct and interpretation of the index test, did not match the review question (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). However, the target condition (as defined by the reference standard) was of high concern due to the fact that diagnosis was made with full access to study results and medical records at four years follow‐up. </p> </section> <section id="CD012883-sec-0054"> <h3 class="title" id="CD012883-sec-0054">Findings</h3> <p>The key characteristics of the study are summarised in <a href="./references#CD012883-sec-0078" title="">Characteristics of included studies</a>. The summary of main results for the only included study is presented in the 'Summary of findings' table (<a href="./full#CD012883-tbl-0001">summary of findings Table</a>). </p> <p><a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a> included data on 45 participants with MCI diagnosed with Petersen criteria (<a href="./references#CD012883-bbs2-0072" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004;256(3):183‐94. ">Petersen 2004</a>), and <a href="./references#CD012883-bbs2-0097" title="WinbladB , PalmerK , KivipeltoM , JelicV , FratiglioniL , WahlundLO , et al. Mild cognitive impairment ‐ beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine2004;256(3):240‐6. ">Winblad 2004</a>. The study used two different assessments to evaluate the PET: visual assessment PET positive if increased tracer uptake was visible in any of four different cerebral regions (frontal, parietal, temporal, and posterior cingulate/precuneus cortices) and quantitative assessment with a SUVR &gt; 1.45 for a positive <sup>18</sup>F‐florbetaben. At four years follow‐up, the diagnosis of ADD was made using NINCDS‐ADRDA criteria (<a href="./references#CD012883-bbs2-0061" title="McKhannGM , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;34(7):939‐44. ">McKhann 1984</a>). Lewy Body dementia was made using <a href="./references#CD012883-bbs2-0059" title="McKeithIG , GalaskoD , KosakaK , PerryEK , DicksonDW , HansenLA , et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology1996;47(5):1113‐24. ">McKeith 1996</a> criteria, FTD diagnosis was made using Lund criteria (<a href="./references#CD012883-bbs2-0066" title="NearyD , SnowdenJS , GustafsonL , PassantU , StussD , BlackS , et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology1998;51(6):1546‐54. ">Neary 1998</a>) and PSP diagnosis was made using (<a href="./references#CD012883-bbs2-0040" title="HauwJJ , DanielSE , DicksonD , HoroupianDS , JellingerK , LantosPL , et al. Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy). Neurology1994;44(11):2015‐9. ">Hauw 1994</a>) criteria. </p> <p><b><sup>18</sup>F‐florbetaben for Alzheimer’s disease dementia (ADD)</b> </p> <p> <ul id="CD012883-list-0016"> <li> <p><b>Visual Assessment</b>: <sup>18</sup>F‐florbetaben PET scan had a sensitivity of 100% (95% CI 84% to 100%) and a specificity of 83% (95% CI 63% to 95%) to predict the progression from MCI to ADD at four years follow‐up. Of 45 participants who were given an initial clinical diagnosis of MCI, 21 were true positive, 4 were false positives, 0 were false negative, and 20 were true negative (<a href="#CD012883-fig-0003">Figure 3</a>). </p> </li> </ul> </p> <div class="figure" id="CD012883-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of tests: 1 18F‐florbetaben visual assessment and progression to ADD, 2 18F‐florbetaben SUVR and progression to ADD, 3 18F‐florbetaben visual assessment and progression to any other form of non‐ADD, 4 18F‐florbetaben SUVR and progression to any other form of non‐ADD, 5 18F‐florbetaben visual assessment and progression to any form of dementia, 6 18F‐florbetaben SUVR and progression to any form of dementia." data-id="CD012883-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of tests: 1 <sup>18</sup>F‐florbetaben visual assessment and progression to ADD, 2 <sup>18</sup>F‐florbetaben SUVR and progression to ADD, 3 <sup>18</sup>F‐florbetaben visual assessment and progression to any other form of non‐ADD, 4 <sup>18</sup>F‐florbetaben SUVR and progression to any other form of non‐ADD, 5 <sup>18</sup>F‐florbetaben visual assessment and progression to any form of dementia, 6 <sup>18</sup>F‐florbetaben SUVR and progression to any form of dementia. </p> </div> </div> </div> <p> <ul id="CD012883-list-0017"> <li> <p><b>SUVR:</b><sup>18</sup>F‐florbetaben PET scan had a sensitivity of 100% (95% CI 84% to 100%) and a specificity of 88% (95% CI 68% to 97%) to predict the progression from MCI to ADD at four years follow‐up. Of 45 participants who were given an initial clinical diagnosis of MCI, 21 were true positive, 3 were false positives, 0 were false negative, and 21 were true negative (<a href="#CD012883-fig-0003">Figure 3</a>). </p> </li> </ul> </p> <p><b><sup>18</sup>F‐florbetaben for any other form of dementia (non‐ADD)</b> </p> <p> <ul id="CD012883-list-0018"> <li> <p><b>Visual Assessment</b>: <sup>18</sup>F‐florbetaben PET scan had a sensitivity of 0.0% (95% CI 0.0% to 52%) and a specificity of 38% (95% CI 23% to 54%) to predict the progression from MCI to any other form of dementia (non‐ADD) at four years follow‐up. Of 45 participants who were given an initial clinical diagnosis of MCI, 0 were true positive; 25 were false positives, 5 were false negative (3 FTD, 1 Lewy body dementia, and 1 PSP), and 15 were true negative (<a href="#CD012883-fig-0003">Figure 3</a>). </p> </li> </ul> <ul id="CD012883-list-0019"> <li> <p><b>SUVR:</b><sup>18</sup>F‐florbetaben PET scan had a sensitivity of 0.0% (95% CI 0.0% to 52%) and a specificity of 40% (95% CI 25% to 57%) to predict the progression from MCI to any other form of dementia (non‐ADD) at four years follow‐up. Of 45 participants who were given an initial clinical diagnosis of MCI, 0 were true positive, 24 were false positives, 5 were false negative (3 FTD, 1 Lewy body dementia and 1 PSP), and 16 were true negative (<a href="#CD012883-fig-0003">Figure 3</a>). </p> </li> </ul> </p> <p><b><sup>18</sup>F‐florbetaben for any form of dementia</b> </p> <p> <ul id="CD012883-list-0020"> <li> <p><b>Visual Assessment</b>: <sup>18</sup>F‐florbetaben PET scan had a sensitivity of 81% (95% CI 61% to 93%) and a specificity of 79% (95% CI 54% to 94%) to predict the progression from MCI to any form of dementia at four years follow‐up. Of 45 participants who were given an initial clinical diagnosis of MCI; 21 were true positive, 4 were false positives, 5 were false negative (3 FTD, 1 Lewy body dementia, and 1 PSP) and 15 were true negative (<a href="#CD012883-fig-0003">Figure 3</a>). </p> </li> </ul> <ul id="CD012883-list-0021"> <li> <p><b>SUVR:</b><sup>18</sup>F‐florbetaben PET scan had a sensitivity of 81% (95% CI 61% to 93%) and a specificity of 84% (95% CI 60% to 97%) to predict the progression from MCI to any form of dementia at four years follow‐up. Of 45 participants who were given an initial clinical diagnosis of MCI, 21 were true positive, 3 were false positives, 5 were false negative (3 FTD, 1 Lewy body dementia, and 1 PSP), and 16 were true negative (<a href="#CD012883-fig-0003">Figure 3</a>). </p> </li> </ul> </p> <p><b>Investigation of heterogeneity</b> </p> <p>We were able to include only one study, therefore, issues of heterogeneity did not arise. </p> <p><b>Sensitivity analyses</b> </p> <p>There were insufficient data to permit any sensitivity analyses.</p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012883-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012883-sec-0055"></div> <section id="CD012883-sec-0056"> <h3 class="title" id="CD012883-sec-0056">Summary of main results</h3> <p>The volume and quality of evidence regarding the DTA of <sup>18</sup>F‐florbetaben for early diagnosis of ADD and other dementias in people with MCI is very limited. We identified only one study in this systematic review and for that reason we were not able to conduct a meta‐analysis, sensitivity analysis, or heterogeneity analyses (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). The results are summarised in a 'Summary of findings' table (<a href="./full#CD012883-tbl-0001">summary of findings Table</a>). The study was evaluated as at high risk of bias, mainly due to the potential conflicts of interest (financial support of the study and also because three authors were employees of the previous company who manufactured the <sup>18</sup>F‐florbetaben tracer and three authors were employees of the current company that manufactures the <sup>18</sup>F‐florbetaben tracer (<a href="./references#CD012883-sec-0078" title="">Characteristics of included studies</a>)). </p> <p>Regarding our objectives: to determine the DTA of the <sup>18</sup>F‐florbetaben PET scan for detecting people with MCI at baseline who will clinically progress to ADD, or to other forms of dementia or any form of dementia at follow‐up, the results were the following: </p> <p><b><sup>18</sup>F‐florbetaben PET scan for Alzheimer’s disease dementia (ADD)</b> </p> <p>Progression from MCI to ADD analysed by visual assessment: sensitivity of 100% (95% CI 84% to 100%) and a specificity of 83% (95% CI 63% to 95%). </p> <p>Progression from MCI to ADD analysed by SUVR &gt; 1.45: sensitivity of 100% (95% CI 84% to 100%) and a specificity of 88% (95% CI 68% to 97%). </p> <p><sup>18</sup>F‐florbetaben has a close to perfect sensitivity and a good specificity for predicting progression to ADD through visual assessment evaluation or SUVR (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). However, a positive <sup>18</sup>F‐florbetaben PET scan for Aβ, has been found in other neurological conditions clinically diagnosed, and it was positive in vascular dementia, frontotemporal dementia and dementia with Lewy bodies (<a href="./references#CD012883-bbs2-0092" title="VillemagneVL , OngK , MulliganRS , HollG , PejoskaS , JonesG , et al. Amyloid imaging with (18)F‐florbetaben in Alzheimer disease and other dementias. Journal of Nuclear Medicine2011;52(8):1210‐7. ">Villemagne 2011</a>). Nevertheless, in one study with 12 cases with non‐ADD at autopsy, the <sup>18</sup>F‐florbetaben PET scan was negative in all of them (<a href="./references#CD012883-bbs2-0082" title="SabbaghMN , SchäubleB , AnandK , RichardsD , MurayamaS , AkatsuH , et al. Histopathology and florbetaben PET in patients incorrectly diagnosed with Alzheimer's disease.. Journal of Alzheimer's Disease2017;56(2):441‐46. ">Sabbagh 2017</a>). On the other hand, in other amyloid biomarkers like PET PiB, the false positive rate could be explained because it has affinity to amyloid in vessel walls, in particular, to cerebral amyloid angiopathy (CAA) (<a href="./references#CD012883-bbs2-0099" title="ZhangS , SmailagicN , HydeC , Noel‐StorrAH , TakwoingiY , McShaneR , et al. 11C‐PIB‐PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD010386.pub2] ">Zhang 2014</a>). We would think that the pathological diagnosis of some patients with clinically probable ADD may be vascular dementia secondary to CAA and some people with MCI may be have vascular MCI due to CAA. </p> <p>As other amyloid tracers, <sup>18</sup>F‐florbetaben has probed the detection of amyloid plaques that are composed of insoluble Aβ peptides (<a href="./references#CD012883-bbs2-0030" title="European Medicines Agency. Neuraceq. Annex 1. Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/002553/WC500162592.pdf (accessed 8th April 2015). ">EMA 2014</a>, <a href="./references#CD012883-bbs2-0033" title="Food , DrugAdministration . Neuroceq. www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf (accessed 08/04/2015). ">FDA 2014</a>), however, the soluble Aβ oligomers have been playing a central role in Alzheimer's pathogenesis in the amyloid hypothesis (<a href="./references#CD012883-bbs2-0043" title="HaydenEY , TeplowDB . Amyloid β‐protein oligomers and Alzheimer’s disease. Alzheimer's Research &amp; Therapy2013;5(6):1‐11. ">Heyden 2013</a>), with the possibility of producing false negatives. In addition, amyloid tracers do not bind to the other histopathologic core of Alzheimer's disease, the neurofibrillary tangles (NFTs). There is evidence that indicates that plaques and tangles independently contribute to cognitive impairment over the clinical course of Alzheimer's disease (<a href="./references#CD012883-bbs2-0089" title="Serrano‐PozoA , QianJ , MonsellSE , FroschMP , BetenskyRA , HymanBT . Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. Journal of Neuropathology and Experimental Neurology2013;72(12):1182‐92. ">Serrano‐Pozo 2013</a><b>).</b> Moreover, in another cohort study, the NFT formation might be either unrelated to amyloid plaques formation or a temporally distinct process, or both<b>(</b><a href="./references#CD012883-bbs2-0081" title="RoyallDR , PalmerRF . The temporospatial evolution of neuritic plaque‐related and independent tauopathies: implications for dementia staging. Journal of Alzheimer’s Disease2014;40(3):541‐9. ">Royall 2014</a><b>).</b> The latest could explain why, in 44 participants with ADD and positive Aβ histopathology, one had a negative <sup>18</sup>F‐florbetaben PET scan (<a href="./references#CD012883-bbs2-0083" title="SabriO , SabbaghMN , SeibylJ , BarthelH , AkatsuH , OuchiY , et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimer's &amp; Dementia2015;11(8):964‐74. ">Sabri 2015</a>). </p> <p>Another important factor to be considered in predicting the progression to ADD is the duration of follow‐up, because the reported progression rate of MCI to ADD is between 8% and 16% per year (<a href="./references#CD012883-bbs2-0063" title="MitchellAJ , Shiri‐FeshkiM . Rate of progression of mild cognitive impairment to dementia ‐ meta‐analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica2009;119(4):252‐65. ">Mitchell 2009</a>). Therefore, a high percentage of people with baseline MCI would progress to Alzheimer’s disease dementia if we could include a longer follow‐up period, which would consequently affect the predictive accuracy of the <sup>18</sup>F‐florbetaben PET scan. However the progression rate at two years was 44% (including two participants who at four years follow‐up reverted to MCI or converted to another form of dementia (non‐ADD)) and at four years was 47%. This is more than normal and probably can be explained by the setting of recruitment or demographic or MCI characteristics and maybe other underlying factors that can increase the progression rate. In addition, in one systematic review regarding the progression from MCI to ADD with PiB PETp‐u, a correlation between longer follow‐up and higher specificities was found (<a href="./references#CD012883-bbs2-0054" title="MaY , ZhangS , LiJ , ZhengDM , GuoY , FengJ , et al. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow‐up: a meta‐analysis. Medicine2014;93(27):1‐12. ">Ma 2014</a>). However, due to the lack of data, we were not able to investigate the effect of the follow‐up on the progression rate from MCI to ADD, or any form of dementia. </p> <p>On the other hand, MCI subtypes have been related to progression to dementia. In a large longitudinal study with 550 MCI participants, evidence were found that the MCI subtype, presence of storage memory impairment, multiple domain condition, and presence of APOE ϵ4 allele increased the risk of progression to dementia. Multivariate survival and Kaplan‐Meier analyses showed that amnestic MCI with storage memory impairment had the most and closest risk of progression to dementia (<a href="./references#CD012883-bbs2-0031" title="EspinosaA , AlegretM , ValeroS , Vinyes‐JunqueG , HernandezI , MauleonA , et al. A longitudinal follow‐up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved. Journal of Alzheimer’s Disease2013;34(3):769‐80. ">Espinosa 2013</a>). Specifically, in our systematic review, the study of Ong 2015 (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>), included amnestic and non‐amnestic MCI, and after adjusting for both <sup>18</sup>F‐florbetaben PET scan positive status and hippocampal atrophy, the hazard ratio for the development of ADD from amnestic MCI was not significant. Additionally, some other risk factors like family history of dementia, APOE ϵ4 allele presence, and Aβ and tau protein levels in cerebrospinal fluid may contribute to a faster progression rate to dementia. In conclusion, further updated systematic reviews should include high quality research with more detailed data about the characteristics of MCI that are required to not only explore the underlying mechanisms but also to elucidate the causal pathways that link <sup>18</sup>F‐florbetaben PET scan positivity of diverse MCI subtypes and disease progression. </p> <p><b><sup>18</sup>F‐florbetaben PET scan for any other forms of dementia (non‐Alzheimer’s disease dementia (non‐ADD))</b> </p> <p>Progression to any other form of non‐ADD analysed by visual assessment: sensitivity of 0.0% (95% CI 0.0% to 52%) and a specificity of 38% (95% CI 23% to 54%). </p> <p>Progression to any other form of non‐ADD analysed by SUVR &gt; 1.45: sensitivity of 0.0% (95% CI 0.0% to 52%) and a specificity of 40% (95% CI 25% to 57%). </p> <p>The study reported only 5 people converting to non‐ADD at four years follow‐up: frontotemporal dementia (3), Lewy body dementia (1) and progressive supranuclear palsy (1); all of them were <sup>18</sup>F‐florbetaben negative (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). </p> <p><sup>18</sup>F‐florbetaben PET scan cortical binding has been observed in non‐ADD; 9% (1/11) of FTLD, 25% (1/4) of VaD, 29% (2/7) of DLB in a study from Australia (<a href="./references#CD012883-bbs2-0092" title="VillemagneVL , OngK , MulliganRS , HollG , PejoskaS , JonesG , et al. Amyloid imaging with (18)F‐florbetaben in Alzheimer disease and other dementias. Journal of Nuclear Medicine2011;52(8):1210‐7. ">Villemagne 2011</a>) and in 11% (3/27) in those with confirmed non‐Alzheimer's disease neurodegenerative pathologies at autopsy (<a href="./references#CD012883-bbs2-0083" title="SabriO , SabbaghMN , SeibylJ , BarthelH , AkatsuH , OuchiY , et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimer's &amp; Dementia2015;11(8):964‐74. ">Sabri 2015</a>). However, in this study none of the five converters to non‐ADD at four years follow‐up were <sup>18</sup>F‐florbetaben positive; the latest could explain the sensitivity of 0% and specificity of 38% with visual assessment in the included study. Nevertheless, according to histopathological studies, we would expect that studies with more participants, or participants with positive PET scans that progress to non‐ADD, could potentially increase the DTA to predict progression to other forms of dementia and decrease the DTA to predict the progression to ADD. </p> <p>The latest data suggested the test was insufficient to evaluate the early diagnostic value for progression from MCI to any form of non‐ADD. </p> <p><b><sup>18</sup>F‐florbetaben PET scan for any form of dementia</b> </p> <p>Progression to any form of dementia analysed by visual assessment: sensitivity of 81% (95% CI 61% to 93%) and a specificity of 79% (95% CI 54% to 94%). </p> <p>Progression to any form of dementia analysed by SUVR &gt; 1.45: sensitivity of 81% (95% CI 61% to 93%) and a specificity of 84% (95% CI 60% to 97%). </p> <p>Ong 2015 reported lower sensitivity and specificity for prediction of any form of dementia other than ADD (<a href="./references#CD012883-bbs2-0001" title="Bahar‐FuchsA , VillemagneV , OngK , ChetélatG , LambF , ReiningerCB , et al. Prediction of amyloid‐β pathology in amnestic mild cognitive impairment with neuropsychological tests. Journal of Alzheimer's Disease2013;33(2):451‐62. OngD , VillemagneV , Bahar‐FuchsA , LambF , JonesG , ReinlingerC , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐Florbetaben. Internal Medicine Journal2011;41 Suppl S3:39. OngK , VillemagneV , Bahar‐FuchsA , LambF , ChetelatG , HollG , et al. Conversion from mild cognitive impairment to Alzheimer's disease over 12 months: predictive value of AB imaging with 18F‐florbetaben. Alzheimer's &amp; Dementia2011;7 Suppl(4):S217. OngK , VillemagneV , Bahar‐FuchsA , LambF , ReiningerC , PutzB , et al. Cognitive change and Ab deposition in MCI subjects studied with serial 18F‐florbetaben PET over 2 years. Alzheimer's &amp; Dementia2012;8 Suppl(4):P22‐3. OngK , VillemagneVL , Bahar‐FuchsA , LambF , JonesG , ReiningerC , et al. A two‐year longitudinal assessment of abeta deposition in MCI with 18f‐florbetaben. Internal Medicine Journal2012;42 Suppl S3:12. OngKT , VillemagneVL , Bahar‐FuchsA , LambF , LangdonN , CatafauAM , et al. Aβ imaging with 18F‐florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry2015;86(4):431‐6. ">Ong 2015</a>). This is explained because the test has a close to perfect sensitivity and good specificity to predict the progression to ADD and if we add the data with those that are PET negative with other types of non‐ADD, the sensitivity decreased to 81% and the specificity to 79%. </p> <p>According to the aforementioned, in the cases of <sup>18</sup>F‐florbetaben PET scans for any other forms of dementia, there are cases that are PET positive with other neurological conditions in the literature, but not in this study; and this paucity of data with this type of participant, could be explained due to the small sample of participants of this study. For that reason, we would expect that in other studies where we would check the progression to any form of dementia, the DTA would be higher because it is probable to find participants with DBL, FTD and others with a PET positive result, and also we would expect an decrease in the DTA to predict the progression to ADD. </p> </section> <section id="CD012883-sec-0057"> <h3 class="title" id="CD012883-sec-0057">Strengths and weaknesses of the review</h3> <p>We conducted an extensive, comprehensive, and sensitive literature search using 11 different electronic databases without any limitation to language or publication status. However, we only identified one study with 45 eligible participants, therefore our DTA estimates are relatively imprecise. This paucity of evidence reflects the very significant challenges inherent in conducting long term prospective studies of well characterised participants, followed up to the point of progression of a clinical dementia. The methodological quality assessment and data syntheses were based on recommended methods. To increase the reliability of our findings, we included only studies that fulfilled delayed verification of progression from MCI to ADD or any other form of dementia (non‐ADD) or any form of dementia at follow‐up. </p> <p>The included study did have significant methodological limitations that weakened confidence in the findings of the review. The study lacked information about the selection of the participants, the reference standard was made with knowledge of the medical studies and medical records, and the major problem was a potential conflict of interest due to the relationship with the companies who produced and produce the tracer. On the other hand, considerable uncertainty remained concerning the clinical diagnosis of ADD; the histopathological diagnosis would be the better way to probe the diagnosis, however, this option is not realistic for a clinical trial. </p> </section> <section id="CD012883-sec-0058"> <h3 class="title" id="CD012883-sec-0058">Applicability of findings to the review question</h3> <p>Regarding the question of this review:</p> <p>Could the <sup>18</sup>F‐florbetaben PET scan identify those people with MCI who would progress to clinical dementia at follow‐up?. There was no applicability concern that the included patients, the setting, the conduct, and interpretation of the index test in the included study did not match the review question. However, there was a high applicability concern about the target condition (as defined by the reference standard) because the diagnosis at follow‐up was made with access to the study tests and medical records for all participants and, therefore, due to the one study included, it was difficult to extend the findings into clinical practice without a meta‐analysis. </p> <p>The diagnostic utility of <sup>18</sup>F‐florbetaben PET scan for identifying Alzheimer’s disease pathology and identifying those people with MCI who would convert to ADD could be affected by a number of factors that have not been determined so far. The most important was the lack of a large study to evaluate this question, as we included one study that addressed the question with only 45 participants at follow‐up. Conducting a <sup>18</sup>F‐florbetaben test is expensive, therefore it is important to clearly demonstrate its accuracy prior to recommending its adoption in clinical practice. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012883-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/urn:x-wiley:14651858:media:CD012883:CD012883-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_t/tCD012883-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram." data-id="CD012883-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012883/full#CD012883-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012883-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/urn:x-wiley:14651858:media:CD012883:CD012883-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_t/tCD012883-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study" data-id="CD012883-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012883/full#CD012883-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012883-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/urn:x-wiley:14651858:media:CD012883:CD012883-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_t/tCD012883-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of tests: 1 18F‐florbetaben visual assessment and progression to ADD, 2 18F‐florbetaben SUVR and progression to ADD, 3 18F‐florbetaben visual assessment and progression to any other form of non‐ADD, 4 18F‐florbetaben SUVR and progression to any other form of non‐ADD, 5 18F‐florbetaben visual assessment and progression to any form of dementia, 6 18F‐florbetaben SUVR and progression to any form of dementia." data-id="CD012883-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of tests: 1 <sup>18</sup>F‐florbetaben visual assessment and progression to ADD, 2 <sup>18</sup>F‐florbetaben SUVR and progression to ADD, 3 <sup>18</sup>F‐florbetaben visual assessment and progression to any other form of non‐ADD, 4 <sup>18</sup>F‐florbetaben SUVR and progression to any other form of non‐ADD, 5 <sup>18</sup>F‐florbetaben visual assessment and progression to any form of dementia, 6 <sup>18</sup>F‐florbetaben SUVR and progression to any form of dementia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012883/full#CD012883-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012883-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/urn:x-wiley:14651858:media:CD012883:CD012883-TST-001" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_t/tCD012883-TST-001.xxx" target="_blank"><b></b></a></p> </div><img alt="18F‐florbetaben visual assessment and progression to ADD." data-id="CD012883-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-TST-001.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 1</div> <div class="figure-caption"> <p><sup>18</sup>F‐florbetaben visual assessment and progression to ADD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012883/references#CD012883-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-TST-001.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012883-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/urn:x-wiley:14651858:media:CD012883:CD012883-TST-002" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_t/tCD012883-TST-002.xxx" target="_blank"><b></b></a></p> </div><img alt="18F‐florbetaben SUVR and progression to ADD." data-id="CD012883-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-TST-002.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 2</div> <div class="figure-caption"> <p><sup>18</sup>F‐florbetaben SUVR and progression to ADD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012883/references#CD012883-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-TST-002.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012883-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/urn:x-wiley:14651858:media:CD012883:CD012883-TST-003" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_t/tCD012883-TST-003.xxx" target="_blank"><b></b></a></p> </div><img alt="18F‐florbetaben visual assessment and progression to any other form of non‐ADD." data-id="CD012883-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-TST-003.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 3</div> <div class="figure-caption"> <p><sup>18</sup>F‐florbetaben visual assessment and progression to any other form of non‐ADD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012883/references#CD012883-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-TST-003.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012883-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/urn:x-wiley:14651858:media:CD012883:CD012883-TST-004" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_t/tCD012883-TST-004.xxx" target="_blank"><b></b></a></p> </div><img alt="18F‐florbetaben SUVR and progression to any other form of non‐ADD." data-id="CD012883-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-TST-004.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 4</div> <div class="figure-caption"> <p><sup>18</sup>F‐florbetaben SUVR and progression to any other form of non‐ADD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012883/references#CD012883-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-TST-004.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012883-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/urn:x-wiley:14651858:media:CD012883:CD012883-TST-005" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_t/tCD012883-TST-005.xxx" target="_blank"><b></b></a></p> </div><img alt="18F‐florbetaben visual assessment and progression to any form of dementia." data-id="CD012883-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-TST-005.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 5</div> <div class="figure-caption"> <p><sup>18</sup>F‐florbetaben visual assessment and progression to any form of dementia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012883/references#CD012883-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-TST-005.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012883-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/urn:x-wiley:14651858:media:CD012883:CD012883-TST-006" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_t/tCD012883-TST-006.xxx" target="_blank"><b></b></a></p> </div><img alt="18F‐florbetaben SUVR and progression to any form of dementia." data-id="CD012883-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-TST-006.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 6</div> <div class="figure-caption"> <p><sup>18</sup>F‐florbetaben SUVR and progression to any form of dementia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012883/references#CD012883-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012883/media/CDSR/CD012883/image_n/nCD012883-TST-006.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012883-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">Diagnostic test accuracy of 18F‐florbetaben to predict the progression to ADD, any other form of dementia (non‐ADD) or any form of dementia in people with MCI</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>What is the diagnostic accuracy of <sup>18</sup>F‐florbetaben PET amyloid biomarker for predict progression to ADD or any other form of dementia (non‐ADD) or any form of dementia in people with MCI? </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Descriptive</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Patient population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Participants diagnosed with MCI at baseline using any of the Petersen criteria or Winblad criteria or CDR = 0.5 or any 16 definitions included by Matthews (<a href="./references#CD012883-bbs2-0056" title="MatthewsFE , StephanBC , McKeithIG , BondJ , BrayneC , Medical Research Council Cognitive Function and Ageing Study. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society2008;56(8):1424‐33. ">Matthews 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sources of referral</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Memory clinic</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MCI criteria</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Petersen criteria 2004 and Winblad 2004 (<a href="./references#CD012883-bbs2-0072" title="PetersenRC . Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine2004;256(3):183‐94. ">Petersen 2004</a>; <a href="./references#CD012883-bbs2-0097" title="WinbladB , PalmerK , KivipeltoM , JelicV , FratiglioniL , WahlundLO , et al. Mild cognitive impairment ‐ beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine2004;256(3):240‐6. ">Winblad 2004</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sampling procedure</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>unclear</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prior testing</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The only testing prior performing the <sup>18</sup>F‐florbetaben PET amyloid biomarker was the application of diagnostic criteria for identifying participants with MCI </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Settings</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Secondary care</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Index test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben PET </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Threshold prespecified at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Threshold interpretation</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Visual and quantitative</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Threshold</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Visual: if any tracer uptake was visible in any of the frontal, parietal, temporal, and posterior cingulate/precuneus cortices </p> <p>SUVR (Standardised Uptake Volume ratio) of ROI: &gt; 1.45</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben retention region </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Visual: frontal, parietal, temporal, and posterior cingulate/precuneus cortices</p> <p>Global cortex (SUVR)</p> <p>SUVR: Global cortex</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference Standard</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>For Alzheimer’s disease dementia:</p> <p>NINCDS‐ADRDA (<a href="./references#CD012883-bbs2-0061" title="McKhannGM , DrachmanD , FolsteinM , KatzmanR , PriceD , StadlanEM . Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology1984;34(7):939‐44. ">McKhann 1984</a>) </p> <p>For Lewy body dementia:</p> <p>McKeith criteria (<a href="./references#CD012883-bbs2-0060" title="McKeithIG , DicksonDW , LoweJ , EmreM , O'BrienJT , FeldmanH , et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology2005;65(12):1863‐72. ">McKeith 2005</a>) </p> <p>For frontotemporal dementia:</p> <p>Lund criteria (<a href="./references#CD012883-bbs2-0017" title="BrunA , EnglundB , GustafsonL , PassantU , MannDMA , NearyD , et al. Clinical and neuropathological criteria for frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry1994;57(4):416‐8. ">Brun 1994</a>) </p> <p>For progressive supranuclear palsy:</p> <p>Preliminary NINDS criteria (<a href="./references#CD012883-bbs2-0040" title="HauwJJ , DanielSE , DicksonD , HoroupianDS , JellingerK , LantosPL , et al. Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy). Neurology1994;44(11):2015‐9. ">Hauw 1994</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target condition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Progression from MCI to Alzheimer’s disease dementia or any other forms of dementia or any form of dementia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Included studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Prospectively well‐defined cohorts with any accepted definition of MCI (as above). One study (N = 45 participants) was included. Number of participants included in analysis: 45. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality concerns</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Patient characteristics were poorly reported. Reference standard diagnosis was made with knowledge of the index test. Applicability concerns were high in reference standard. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Limitations</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>We were not able to calculate a summary of sensitivity and specificity due to insufficient number of studies. </p> <p>Investigation of heterogeneity and sensitivity analysis were not done due to insufficient number of studies. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Studies</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Cases/Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Sensitivity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Specificity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Consequences in a cohort of 100</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Proportion converting<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Missed cases<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overdiagnosed</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alzheimer's disease dementia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben (visual assessment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (95% CI 84% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% (95% CI 63% to 95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben (SUVR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (95% CI 84% to 100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88% (95% CI 68% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any other form of dementia (non‐ADD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben (visual assessment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% (95% CI 0% to 52%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38% (95% CI 23% to 54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben (SUVR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0% (95% CI 0% to 52%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40% (95% CI 25% to 57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Any form of dementia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben (visual assessment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81% (95% CI 61% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79% (95% CI 54% to 94%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><sup>18</sup>F‐florbetaben (SUVR) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81% (95% CI 61% to 93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84% (95% CI 60% to 97%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Investigation of heterogeneity and sensitivity analysis</b>: The planned investigations of heterogeneity or sensitivity analyses were not possible due to a limited number of studies available for each analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Conclusions:</b><sup>18</sup>F‐florbetaben PET scan has a good sensitivity achieved especially in predicting the progression from MCI to ADD. The quality of evidence was weak because it was based on only one study (45 participants) and there was high risk of bias due to the knowledge of the reference standard to do the diagnosis at four‐year follow‐up and due to possible conflict of interest detected. There is a need for conducting studies using standardised <sup>18</sup>F‐florbetaben PET scan methodology in larger populations. Regarding the aforementioned we do not recommend the use in clinical practice until the DTA performance will be clearly demonstrated. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1. Proportion converting to ADD or any other form of dementia (non‐ADD) or any form of dementia in the included study</sup> </p> <p><sup>2. Missed and overdiagnosed numbers were computed using the proportion converting to the target condition.</sup> </p> <p><sup>ADD: Alzheimer's disease dementia<br/> CDR: Clinical Dementia Rating<br/> MCI: Mild cognitive impairment<br/> NINCDS‐ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association</sup> </p> <p><sup>NINDS: National Institute of Neurological Disorders and Stroke<br/> PET: Positron emission tomography<br/> ROI: Region of interest<br/> SUVR: Standardised uptake value ratio</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings</span> <span class="table-title">Diagnostic test accuracy of 18F‐florbetaben to predict the progression to ADD, any other form of dementia (non‐ADD) or any form of dementia in people with MCI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012883/full#CD012883-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012883-tbl-0002"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p>Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">1 <sup>18</sup>F‐florbetaben visual assessment and progression to ADD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">2 <sup>18</sup>F‐florbetaben SUVR and progression to ADD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">3 <sup>18</sup>F‐florbetaben visual assessment and progression to any other form of non‐ADD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">4 <sup>18</sup>F‐florbetaben SUVR and progression to any other form of non‐ADD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">5 <sup>18</sup>F‐florbetaben visual assessment and progression to any form of dementia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">6 <sup>18</sup>F‐florbetaben SUVR and progression to any form of dementia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012883/references#CD012883-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012883&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012883-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012883-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012883-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD012883-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012883-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012883-note-0009">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012883\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012883\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012883\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012883"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012883\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012883\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012883\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012883\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012883\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012883"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012883\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012883\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012883\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012883"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012883\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012883\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012883\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012883"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=fw9sVDQH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012883&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012883';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012883/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012883/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012883%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725773853"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012883/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725773857"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012883/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e83701abd936d',t:'MTc0MDcyNTc3NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 